<!DOCTYPE html>
<html lang="fa">
 <meta content="text/html;charset=utf-8" http-equiv="content-type"/>
 <head>
  <title>
   Bronchiectasis in adults: Maintaining lung health
  </title>
  <link href="d/css/1.css" rel="stylesheet"/>
 </head>
 <body>
  <!-- Start Main Menu Area -->
  <br/>
  <br/>
  <br/>
  <br/>
  <div class="container">
   <div class="row">
   </div>
  </div>
  <section class="teacher-area ptb-10">
   <div class="container">
   </div>
   <section class="course-details-area ptb-60">
    <div class="container">
     <div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
      <h1 style="text-align:center">
       Bronchiectasis in adults: Maintaining lung health
      </h1>
      <div class="utdArticleSection utdStyle" id="topicContent">
       <div id="topicTitle">
        Bronchiectasis in adults: Maintaining lung health
       </div>
       <div class="authorSectionElem">
        <div class="authorsElementsLeft">
         <dl id="topicContributors">
          <dt>
           <span>
           </span>
           Author:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Alan F Barker, MD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Section Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            James K Stoller, MD, MS
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Deputy Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Paul Dieffenbach, MD
           </a>
          </dd>
         </dl>
        </div>
        <div class="authorsElementsRight">
         <div id="literatureReviewDate">
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             Literature review current through:
            </span>
            Jan 2024.
           </bdi>
          </div>
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             This topic last updated:
            </span>
            Oct 05, 2023.
           </bdi>
          </div>
         </div>
        </div>
       </div>
       <div id="topicWhatsNewContainer">
       </div>
       <div id="topicText">
        <p class="headingAnchor" id="H3398304516">
         <span class="h1">
          INTRODUCTION
         </span>
         <span class="headingEndMark">
          —
         </span>
         Bronchiectasis is a condition of chronic cough and daily viscid sputum production associated with airway dilatation and bronchial wall thickening. Multiple conditions are associated with the development of bronchiectasis, but all require an infectious insult and usually also impaired drainage, airway obstruction, and/or a defect in host defense.
        </p>
        <p>
         Of the broad spectrum of causes of noncystic fibrosis bronchiectasis, only a few respond to direct treatment (eg, certain immunodeficiencies, nontuberculous mycobacterial infection, allergic bronchopulmonary aspergillosis). Instead, treatment of bronchiectasis is aimed at controlling infection, reducing inflammation, and improving bronchial hygiene [
         <a href="#rid1">
          1,2
         </a>
         ]. Surgical extirpation of affected areas may be useful in selected patients with focal disease.
        </p>
        <p>
         The treatment of bronchiectasis will be reviewed here. The diagnosis and treatment of cystic fibrosis and the clinical manifestations and diagnosis of bronchiectasis are discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/6367.html" rel="external">
          "Cystic fibrosis: Clinical manifestations and diagnosis"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/6372.html" rel="external">
          "Cystic fibrosis: Overview of the treatment of lung disease"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/6371.html" rel="external">
          "Cystic fibrosis: Antibiotic therapy for chronic pulmonary infection"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/1444.html" rel="external">
          "Clinical manifestations and diagnosis of bronchiectasis in adults"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H2608146794">
         <span class="h1">
          NONPHARMACOLOGIC THERAPIES
         </span>
        </p>
        <p class="headingAnchor" id="H1843043730">
         <span class="h2">
          Avoidance of lung irritants
         </span>
         <span class="headingEndMark">
          —
         </span>
         We advise patients to avoid exposure to respiratory irritants as much as possible. In particular, we strongly encourage cessation of smoking tobacco and vaping. Other irritants, such as smoke from indoor fires and occupational exposures (eg, cleaning agents, dust, fumes), should also be avoided. (See
         <a class="medical medical_review" href="/z/d/html/16634.html" rel="external">
          "Overview of smoking cessation management in adults"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/98400.html" rel="external">
          "Vaping and e-cigarettes"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/562.html" rel="external">
          "Trigger control to enhance asthma management", section on 'Irritants (including cigarette smoke)'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H1633365918">
         <span class="h2">
          Airway clearance therapy
         </span>
         <span class="headingEndMark">
          —
         </span>
         We suggest that all patients with bronchiectasis utilize regular physiotherapy to clear airway secretions  (
         <a class="graphic graphic_table graphicRef78373" href="/z/d/graphic/78373.html" rel="external">
          table 1
         </a>
         ) [
         <a href="#rid2">
          2-4
         </a>
         ]. Bronchiectasis is the prototypical disease for which secretion loosening combined with enhanced removal techniques should be salutary, although large population and long-term studies of efficacy are lacking [
         <a href="#rid4">
          4,5
         </a>
         ]. Based on clinical experience, airway clearance techniques (also known as bronchial hygiene) improve cough [
         <a href="#rid6">
          6
         </a>
         ] and help patients to expectorate the tenacious secretions and mucous plugs that frequently complicate bronchiectasis.
        </p>
        <p>
         Numerous airway clearance techniques and devices exist to loosen viscid secretions mechanically; the most popular are listed in the table  (
         <a class="graphic graphic_table graphicRef78373" href="/z/d/graphic/78373.html" rel="external">
          table 1
         </a>
         ) [
         <a href="#rid7">
          7
         </a>
         ]. The choice of a technique or device should be based upon frequency and tenacity of phlegm, patient comfort, cost, and the patient's ability to use the technique or device with minimal interference to their lifestyle and minimal detriment to coexisting medical conditions [
         <a href="#rid8">
          8
         </a>
         ]. Patient education in the ambulatory setting may enhance adherence [
         <a href="#rid9">
          9
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/6372.html" rel="external">
          "Cystic fibrosis: Overview of the treatment of lung disease", section on 'Chest physiotherapy'
         </a>
         .)
        </p>
        <p>
         Oscillatory positive expiratory pressure (PEP) devices combine PEP with high frequency oscillations to loosen respiratory secretions and move them toward the mouth. Each treatment involves 6 to 10 cycles of a deep inhalation, two to three second breath hold, exhalation through the device which creates oscillations, and coughing. In a systematic review of nine studies (213 participants), daily oscillatory PEP for four weeks was associated with improved health, compared with breathing exercises without a device, but no difference was noted in amount of sputum expectorated, breathlessness, or lung function compared with other airway clearance therapies [
         <a href="#rid10">
          10
         </a>
         ]. The overall quality of evidence was deemed to be low. Further study is needed to determine whether oscillatory PEP has benefits over other airway clearance therapies during exacerbations or with long-term use.
        </p>
        <p class="headingAnchor" id="H2558501531">
         <span class="h2">
          Mucolytic agents and airway hydration
         </span>
         <span class="headingEndMark">
          —
         </span>
         A variety of agents, such as nebulized hypertonic
         <a class="drug drug_general" data-topicid="9929" href="/z/d/drug information/9929.html" rel="external">
          saline
         </a>
         solution,
         <a class="drug drug_general" data-topicid="9587" href="/z/d/drug information/9587.html" rel="external">
          mannitol
         </a>
         , and mucolytic agents, have been developed to help patients clear their airways of secretions. We use nebulized hypertonic saline in selected patients, but do
         <strong>
          not
         </strong>
         use inhaled mannitol or mucolytic agents such as
         <a class="drug drug_general" data-topicid="9317" href="/z/d/drug information/9317.html" rel="external">
          acetylcysteine
         </a>
         and Dornase alpha. (See
         <a class="medical medical_review" href="/z/d/html/1456.html" rel="external">
          "Role of mucoactive agents and secretion clearance techniques in COPD"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/6372.html" rel="external">
          "Cystic fibrosis: Overview of the treatment of lung disease", section on 'Inhaled airway clearance agents'
         </a>
         .)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Nebulized hypertonic
         </strong>
         <a class="drug drug_general" data-topicid="9929" href="/z/d/drug information/9929.html" rel="external">
          saline
         </a>
         – Nebulized hypertonic (6 to 7 percent) saline has been studied as a mucokinetic therapy [
         <a href="#rid11">
          11,12
         </a>
         ]. The mechanism of action is thought to be related to improved mucus rheology, increased ciliary motility, and enhanced cough clearance. Another possibility, suggested by in vitro data, is that low mucus salinity rather than under hydration contributes to mucus retention, which is counteracted by hypertonic saline [
         <a href="#rid13">
          13
         </a>
         ]. Based on clinical experience, we use hypertonic saline in patients with tenacious or copious phlegm to augment expectoration.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         The efficacy of nebulized hypertonic
         <a class="drug drug_general" data-topicid="9929" href="/z/d/drug information/9929.html" rel="external">
          saline
         </a>
         (6 percent) was examined in 40 patients with bronchiectasis who were randomly assigned to treatments with hypertonic or isotonic saline daily for 12 months [
         <a href="#rid14">
          14
         </a>
         ]. No between group differences were found in exacerbation rates, quality of life, forced expiratory volume in one second (FEV
         <sub>
          1
         </sub>
         ), or sputum colonization.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Nebulized hypertonic
         <a class="drug drug_general" data-topicid="9929" href="/z/d/drug information/9929.html" rel="external">
          saline
         </a>
         is beneficial in patients with cystic fibrosis who are age six or older. (See
         <a class="medical medical_review" href="/z/d/html/6372.html" rel="external">
          "Cystic fibrosis: Overview of the treatment of lung disease", section on 'Inhaled airway clearance agents'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Inhaled
         </strong>
         <a class="drug drug_general" data-topicid="9587" href="/z/d/drug information/9587.html" rel="external">
          mannitol
         </a>
         – Mannitol is a hyperosmolar agent that is thought to hydrate airway secretions, which might improve mucus clearance. However, clinical trials have failed to meet primary efficacy end-points in bronchiectasis, and the available evidence does not suggest benefit for inhaled mannitol in noncystic fibrosis bronchiectasis [
         <a href="#rid12">
          12,15
         </a>
         ]. As an example, a multicenter trial (the largest therapeutic trial in bronchiectasis) randomly assigned 461 patients to inhale dry powder mannitol 400 mg or mannitol 50 mg (control) twice daily for 52 weeks [
         <a href="#rid15">
          15
         </a>
         ]. The low dose of mannitol was used as the negative control as it has the same taste and sensation characteristics as the full dose but was ineffective in a prior dose-ranging study. The exacerbation rate was not significantly reduced by mannitol 400 mg (RR 0.92, 95% CI 0.78-1.08). Modest, but significant improvements were noted in time to first exacerbation (165 versus 124 days for mannitol and control, respectively, p = 0.021), days of antibiotics to treat exacerbations, and quality of life by St. George’s Respiratory Questionnaire (SGRQ). A post hoc reanalysis of this trial and a prospective analysis of 333 patients followed in a Scottish registry showed that patients with the highest symptom burden (by SGRQ) had increased time to first exacerbation and fewer exacerbations with mannitol compared with placebo, while patients with lower symptom burden did not benefit [
         <a href="#rid16">
          16
         </a>
         ]. This is the first study that suggests clinical trials should focus on symptom burden (cough, sputum production, dyspnea).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Dry powder
         <a class="drug drug_general" data-topicid="9587" href="/z/d/drug information/9587.html" rel="external">
          mannitol
         </a>
         for inhalation is approved in many countries but not in the United States for bronchoprovocation testing and to improve mucus clearance. While adverse events are not generally more frequent with mannitol than with placebo, changes in airway osmolarity caused by mannitol inhalation can lead to mast cell mediator release and bronchoconstriction in patients with asthma. Thus, mannitol use can only be considered in patients with bronchiectasis who do not have asthma or have a negative mannitol provocation test. (See
         <a class="medical medical_review" href="/z/d/html/525.html" rel="external">
          "Bronchoprovocation testing", section on 'Mannitol'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Mucolytic agents (
         </strong>
         <a class="drug drug_general" data-topicid="9317" href="/z/d/drug information/9317.html" rel="external">
          acetylcysteine
         </a>
         <strong>
          , Dornase alpha)
         </strong>
         – Studies of mucolytic agents have yielded variable results [
         <a href="#rid17">
          17
         </a>
         ]. Acetylcysteine, a mucolytic agent that cleaves disulfide bonds in glycoproteins, has not demonstrated clear benefit among patients with cystic fibrosis (CF), and there are no well-designed studies in non-CF-related bronchiectasis [
         <a href="#rid18">
          18
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Aerosolized Dornase alfa (recombinant deoxyribonuclease, also called DNase), which breaks down DNA (a major gelatinous product of neutrophils), improves pulmonary function (FEV
         <sub>
          1
         </sub>
         ) and reduces hospitalizations in patients with CF [
         <a href="#rid19">
          19
         </a>
         ], but is not effective in non-CF-related bronchiectasis and is potentially harmful [
         <a href="#rid20">
          20
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/1456.html" rel="external">
          "Role of mucoactive agents and secretion clearance techniques in COPD"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Systemic hydration
         </strong>
         – Maintenance of euvolemia with oral liquids is a logical, although unstudied, approach to avoiding inspissation of secretions. There is no evidence that hydration beyond euvolemia provides any benefit.
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H3225314925">
         <span class="h2">
          Pulmonary rehabilitation
         </span>
         <span class="headingEndMark">
          —
         </span>
         Pulmonary rehabilitation is efficacious in chronic obstructive pulmonary disease (COPD), and a few small studies support a benefit in patients with bronchiectasis [
         <a href="#rid21">
          21
         </a>
         ]. The benefits are similar to COPD with comparable improvements in validated scoring questionnaires and numbers of patients completing a program [
         <a href="#rid22">
          22
         </a>
         ].
        </p>
        <p>
         We generally offer participation in pulmonary rehabilitation to patients with impaired exercise capacity, similar to the guidelines for COPD [
         <a href="#rid23">
          23
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/1463.html" rel="external">
          "Pulmonary rehabilitation"
         </a>
         .)
        </p>
        <p>
         Maintaining fitness may actually be associated with reduced bronchiectasis. A secondary analysis of young individuals participating in a fitness study was performed at 25 years. Fitness was defined as duration of time on a standard treadmill program. Women and men with the highest level of fitness had the least incidence of bronchiectasis on chest CT (but no chest CT at baseline 25 years earlier) and reduced cough and phlegm compared with individuals with lower levels of fitness [
         <a href="#rid24">
          24
         </a>
         ].
        </p>
        <p>
         Nutritional supplementation may provide additional benefit beyond that of pulmonary rehabilitation in patients with bronchiectasis. In a randomized trial of 30 well-nourished patients with bronchiectasis participating in a 12 week rehabilitation program, the group receiving a high-protein nutrition supplement enriched with hydroxyl-beta-methylbutyrate (may have anti-catabolic and anti-inflammatory effects) resulted in greater improvement in certain parameters of strength and physical functioning (QOL-B questionnaire), compared with the group participating in pulmonary rehabilitation alone [
         <a href="#rid25">
          25
         </a>
         ]. The role of nutritional support in bronchiectasis needs further study. (See
         <a class="medical medical_review" href="/z/d/html/1440.html" rel="external">
          "Malnutrition in advanced lung disease"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H3934607579">
         <span class="h2">
          Infection control
         </span>
         <span class="headingEndMark">
          —
         </span>
         Communicability and cross-infection with respiratory pathogens (eg,
         <em>
          Pseudomonas aeruginosa
         </em>
         ,
         <em>
          Burkholderia cepacia
         </em>
         , methicillin-resistant
         <em>
          Staphylococcus aureus
         </em>
         [MRSA]) are important concerns in CF (see
         <a class="medical medical_review" href="/z/d/html/6371.html" rel="external">
          "Cystic fibrosis: Antibiotic therapy for chronic pulmonary infection", section on 'Infection prevention and control'
         </a>
         ). Data regarding cross-infection risk among patients with noncystic fibrosis bronchiectasis are limited, but suggest that the risk is low [
         <a href="#rid26">
          26
         </a>
         ]. An expert panel has offered guidelines regarding contact precautions and hand hygiene in specialty clinics and group meetings and urged further research [
         <a href="#rid26">
          26
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H1084041684">
         <span class="h1">
          TREATING THE UNDERLYING DISEASES AND COMORBIDITIES
         </span>
        </p>
        <p class="headingAnchor" id="H3616309383">
         <span class="h2">
          Underlying diseases that need treatment
         </span>
         <span class="headingEndMark">
          —
         </span>
         For most causes of bronchiectasis, treatment of the underlying disease is not possible, as the bronchiectasis is a manifestation of scarring that resulted from a prior injury or infection (eg, severe pneumonia) or a result of an ongoing problem with secretion clearance that does not have a specific treatment (eg, primary ciliary dysfunction). However, some disease processes can be controlled to prevent further scarring. The evaluation and diagnosis of the underlying causes of bronchiectasis are discussed separately  (
         <a class="graphic graphic_table graphicRef56821" href="/z/d/graphic/56821.html" rel="external">
          table 2
         </a>
         and
         <a class="graphic graphic_table graphicRef69598" href="/z/d/graphic/69598.html" rel="external">
          table 3
         </a>
         and
         <a class="graphic graphic_table graphicRef81561" href="/z/d/graphic/81561.html" rel="external">
          table 4
         </a>
         ). (See
         <a class="medical medical_review" href="/z/d/html/1444.html" rel="external">
          "Clinical manifestations and diagnosis of bronchiectasis in adults"
         </a>
         .)
        </p>
        <p>
         Examples of disease processes for which specific therapies may prevent or delay progression of bronchiectasis include the following:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Nontuberculous mycobacterial infection
         </strong>
         – While nontuberculous mycobacterial infection can be an opportunistic infection in a patient with bronchiectasis, it can also be a primary cause of bronchiectasis [
         <a href="#rid27">
          27-29
         </a>
         ]. The diagnosis and treatment are described separately. (See
         <a class="medical medical_review" href="/z/d/html/5342.html" rel="external">
          "Overview of nontuberculous mycobacterial infections"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/5341.html" rel="external">
          "Treatment of
          <i>
           Mycobacterium avium
          </i>
          complex pulmonary infection in adults"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Primary immunodeficiency
         </strong>
         – Certain primary immunodeficiencies, such as common variable immunodeficiency, can be treated with
         <a class="drug drug_general" data-topicid="16471" href="/z/d/drug information/16471.html" rel="external">
          immune globulin
         </a>
         , intravenously (IVIG) or subcutaneously (SCIG). The use of these preparations is discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/3911.html" rel="external">
          "Immune globulin therapy in inborn errors of immunity"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         In addition, caution is required when deciding which vaccinations are safe to administer to patients with primary immunodeficiency  (
         <a class="graphic graphic_table graphicRef110756" href="/z/d/graphic/110756.html" rel="external">
          table 5
         </a>
         ). (See
         <a class="medical medical_review" href="/z/d/html/106521.html" rel="external">
          "Immunizations in patients with inborn errors of immunity"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Recurrent aspiration
         </strong>
         – Treatment of recurrent aspiration due to swallowing difficulties or severe gastroesophageal reflux with aspiration may help prevent progression of bronchiectasis. (See
         <a class="medical medical_review" href="/z/d/html/2237.html" rel="external">
          "Oropharyngeal dysphagia: Clinical features, diagnosis, and management"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/2239.html" rel="external">
          "Approach to refractory gastroesophageal reflux disease in adults"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Allergic bronchopulmonary aspergillosis (ABPA)
         </strong>
         – In ABPA, central bronchiectasis is caused by an inflammatory response to aspergillus colonization of the airway and is treated with glucocorticoids and antifungal agents. (See
         <a class="medical medical_review" href="/z/d/html/104431.html" rel="external">
          "Treatment of allergic bronchopulmonary aspergillosis", section on 'Treatment'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Immune diseases
         </strong>
         – Immune diseases, such as rheumatoid arthritis (RA), inflammatory bowel disease, granulomatosis with polyangiitis (GPA), and sarcoidosis, are sometimes associated with bronchiectasis. A retrospective review of patients from a multi-center rheumatology clinic with RA and bronchiectasis (by chest CT) suggested that patients treated with
         <a class="drug drug_general" data-topicid="9616" href="/z/d/drug information/9616.html" rel="external">
          rituximab
         </a>
         had fewer exacerbations and longer survival over 10 years than those treated with TNF inhibitors [
         <a href="#rid30">
          30
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/4380.html" rel="external">
          "Overview of pleuropulmonary diseases associated with rheumatoid arthritis", section on 'Bronchiectasis'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/4344.html" rel="external">
          "Pulmonary complications of inflammatory bowel disease", section on 'Airway involvement'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/4359.html" rel="external">
          "Treatment of pulmonary sarcoidosis: Initial approach"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Sinus disease
         </strong>
         – Among causes of bronchiectasis, several affect both the upper and lower airways (eg, primary ciliary dysfunction, immune deficiency, GPA, eosinophilic granulomatosis with polyangiitis) and the sinus disease contributes to symptom burden and flares of bronchiectasis. Many patients with bronchiectasis have accompanying rhinosinus disease (infections, polyps) and post-nasal drainage. Treatment of infected sinuses may improve control of bronchiectasis. In a nonrandomized study of 161 patients with rhinosinusitis and bronchiectasis, there was an improvement in clinical symptoms, numerical scoring systems, and reduced exacerbations in the sinus endoscopic surgery group compared with the medication alone group. The forced expiratory volume in one second (FEV
         <sub>
          1
         </sub>
         ) was unchanged at six months in both groups [
         <a href="#rid31">
          31
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/3412.html" rel="external">
          "Microbiology and antibiotic management of chronic rhinosinusitis"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/7528.html" rel="external">
          "Chronic rhinosinusitis: Clinical manifestations, pathophysiology, and diagnosis"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Tracheomalacia and tracheobronchomegaly
         </strong>
         – Patients with symptomatic bronchiectasis due to tracheobronchomegaly (eg, Mounier-Kuhn syndrome) or tracheomalacia, may benefit from placement of a stent or tracheobronchoplasty to maintain airway patency and improve secretion clearance [
         <a href="#rid32">
          32
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/140488.html" rel="external">
          "Tracheomalacia in adults: Treatment and prognosis"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H1471471862">
         <span class="h2">
          Treatment of comorbid disease
         </span>
         <span class="headingEndMark">
          —
         </span>
         Patients with bronchiectasis have a median of four comorbidities [
         <a href="#rid33">
          33,34
         </a>
         ]. Comorbidities that contribute to mortality and risk of hospitalization include malignancy, chronic obstructive pulmonary disease (COPD), cognitive impairment, inflammatory bowel disease, chronic liver disease, iron deficiency anemia, peripheral vascular disease, diabetes mellitus, asthma, pulmonary hypertension, and ischemic heart disease [
         <a href="#rid34">
          34
         </a>
         ]. In particular, we review spirometry and chest computed tomography for evidence of COPD and asthma as the symptoms overlap and exacerbations of COPD and asthma can mimic exacerbations of bronchiectasis and occur concurrently. (See
         <a class="medical medical_review" href="/z/d/html/528.html" rel="external">
          "Acute exacerbations of asthma in adults: Home and office management"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/119093.html" rel="external">
          "Acute exacerbations of asthma in adults: Emergency department and inpatient management"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/1461.html" rel="external">
          "COPD exacerbations: Management"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H3572745376">
         <span class="h1">
          ANTIBIOTICS FOR PREVENTION OF EXACERBATIONS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Frequent exacerbations are the strongest predictor of future exacerbations and are associated with increased hospitalizations, reduced quality of life, and increased mortality [
         <a href="#rid35">
          35
         </a>
         ]. Retained purulent secretions and the associated inflammatory cells and mediators are an important cause of airflow obstruction, airway injury, and exacerbations in bronchiectasis [
         <a href="#rid36">
          36
         </a>
         ]. Thus, reducing the microbial load with selective use of antibiotics and clearing secretions form the cornerstone of preventive therapy.
        </p>
        <p>
         A variety of suppressive or preventive antibiotic regimens have been studied as methods to reduce the frequency of exacerbations and prevent further loss of lung function. Studies that would guide the choice of oral versus inhaled antibiotics in this setting have not been performed [
         <a href="#rid37">
          37
         </a>
         ]. A practical approach to antibiotic selection supported by the European Respiratory Guidelines is provided in the following sections [
         <a href="#rid2">
          2
         </a>
         ].
        </p>
        <p>
         One difficult issue is chronic infection with
         <em>
          Pseudomonas aeruginosa
         </em>
         , which has a propensity to persist in damaged (eg, bronchiectatic) airways, possibly due to its ability to produce virulence factors and to circumvent immune defenses with quorum signaling and biofilm production.
         <em>
          Pseudomonas
         </em>
         can also interact adversely and directly with the airway epithelial surface and the cystic fibrosis conductance regulator (CFTR) protein [
         <a href="#rid38">
          38
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/6368.html" rel="external">
          "Cystic fibrosis: Genetics and pathogenesis", section on 'Chronic lung infection'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/3142.html" rel="external">
          "Epidemiology, microbiology, and pathogenesis of Pseudomonas aeruginosa infection", section on 'Chronic infection in cystic fibrosis'
         </a>
         .)
        </p>
        <p>
         Patients with chronic
         <em>
          P. aeruginosa
         </em>
         infection have reduced quality of life indices, more extensive bronchiectasis on computed tomography (CT), accelerated decline in pulmonary function, and increased number of hospitalizations, compared with patients colonized with
         <em>
          Haemophilus influenzae
         </em>
         [
         <a href="#rid39">
          39,40
         </a>
         ]. For this reason, attempts are often made to reduce the burden of
         <em>
          P. aeruginosa
         </em>
         infection.
        </p>
        <p class="headingAnchor" id="H2136981708">
         <span class="h2">
          Macrolides
         </span>
        </p>
        <p class="headingAnchor" id="H3561187582">
         <span class="h3">
          Patient selection (indications, contraindications, caveats)
         </span>
         <span class="headingEndMark">
          —
         </span>
         For patients with bronchiectasis who have recurrent exacerbations (two to three or more per year) and do not have
         <em>
          P. aeruginosa
         </em>
         infection, we suggest preventive therapy with a macrolide antibiotic, in accordance with the European Respiratory Society (ERS) guidelines [
         <a href="#rid2">
          2
         </a>
         ]. For patients with chronic
         <em>
          P. aeruginosa
         </em>
         in their sputum, inhaled anti-pseudomonal antibiotics are preferred as an initial choice (see
         <a class="local">
          'Inhaled antibiotics'
         </a>
         below). Patients who have
         <em>
          P. aeruginosa
         </em>
         but cannot take an inhaled antibiotic and those who continue to have exacerbations despite inhaled antibiotic may benefit from macrolide therapy as an alternative to or in addition to inhaled antibiotic. Among macrolides, we prefer
         <a class="drug drug_general" data-topicid="9041" href="/z/d/drug information/9041.html" rel="external">
          azithromycin
         </a>
         as most of the supportive data are with this agent [
         <a href="#rid41">
          41
         </a>
         ].
        </p>
        <p>
         As nontuberculous mycobacteria (NTM) are commonly isolated among patients with bronchiectasis (63 percent of patients) [
         <a href="#rid29">
          29
         </a>
         ], some experts (and we agree) obtain sputum stains and cultures for mycobacteria prior to initiating long-term
         <a class="drug drug_general" data-topicid="9041" href="/z/d/drug information/9041.html" rel="external">
          azithromycin
         </a>
         therapy. Preventive monotherapy with a macrolide antibiotic is NOT initiated if NTM are identified on culture to avoid development of resistant organisms. (See
         <a class="medical medical_review" href="/z/d/html/6372.html" rel="external">
          "Cystic fibrosis: Overview of the treatment of lung disease", section on 'Azithromycin'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/1435.html" rel="external">
          "Bronchiectasis in adults: Treatment of acute and recurrent exacerbations", section on 'Nontuberculous mycobacterial infection'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H781388802">
         <span class="h3">
          Dose and duration
         </span>
         <span class="headingEndMark">
          —
         </span>
         For most adults,
         <a class="drug drug_general" data-topicid="9041" href="/z/d/drug information/9041.html" rel="external">
          azithromycin
         </a>
         is administered 500 mg three times weekly [
         <a href="#rid42">
          42
         </a>
         ] or 250 mg once daily [
         <a href="#rid43">
          43
         </a>
         ]. If gastrointestinal complaints are interfering, a dose of 250 mg three times weekly is acceptable. While clinical trials have examined durations of therapy of 6 and 12 months, we typically continue azithromycin indefinitely in patients who are tolerating it well and are having fewer exacerbations than prior to initiating therapy. Some patients will have increased cough and increased exacerbations after pausing azithromycin. For that reason we maintain it through the year unless adverse events appear.
        </p>
        <p class="headingAnchor" id="H83047597">
         <span class="h3">
          Efficacy
         </span>
         <span class="headingEndMark">
          —
         </span>
         Four independently performed systematic reviews and meta-analyses, which included the three large trials listed below, concluded favorable efficacy for chronic macrolide therapy in terms of reduced exacerbations (OR 0.34, 95% CI 0.22-0.54, 341 participants), sputum volume, and symptoms based on improved St. George Respiratory Questionnaire (SGRQ) scores and improved dyspnea index [
         <a href="#rid41">
          41,44-46
         </a>
         ]. Daily or three times weekly use of a macrolide has also been found to be efficacious in the management of bronchiectasis due to cystic fibrosis (CF). (See
         <a class="medical medical_review" href="/z/d/html/6372.html" rel="external">
          "Cystic fibrosis: Overview of the treatment of lung disease", section on 'Azithromycin'
         </a>
         .)
        </p>
        <p>
         Three multicenter, randomized trials have shown reduced rates of exacerbations with use of a macrolide as compared to placebo in patients with noncystic fibrosis bronchiectasis.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         In the Effectiveness of Macrolides in patients with Bronchiectasis using
         <a class="drug drug_general" data-topicid="9041" href="/z/d/drug information/9041.html" rel="external">
          Azithromycin
         </a>
         to Control Exacerbations (EMBRACE) trial, 141 patients with at least one exacerbation of bronchiectasis in the prior year were randomly assigned to take azithromycin 500 mg or placebo, orally three times a week for six months [
         <a href="#rid42">
          42
         </a>
         ]. Azithromycin was associated with a decrease in exacerbations compared with placebo (0.59 per patient with azithromycin and 1.57 per patient with placebo, respectively; RR 0.38, 95% CI 0.26–0.54). However, no significant difference was noted in lung function or quality of life.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         In the Bronchiectasis and Long-term
         <a class="drug drug_general" data-topicid="9041" href="/z/d/drug information/9041.html" rel="external">
          Azithromycin
         </a>
         treatment (BAT) trial, 83 patients with three or more exacerbations of noncystic fibrosis bronchiectasis in the prior year were randomly assigned to take azithromycin 250 mg or placebo daily for 12 months [
         <a href="#rid43">
          43
         </a>
         ]. The median number of exacerbations was zero in the azithromycin group and two in the placebo group. Thirty-two placebo-treated versus 20 azithromycin-treated individuals had at least one exacerbation (hazard ratio, 0.29 [95% CI, 0.16-0.51]). However, the rate of colonization with azithromycin resistant organisms was 88 percent in the azithromycin group and 26 percent in the placebo group. Abdominal pain and diarrhea were more common in the azithromycin group.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         The Bronchiectasis and Low-dose
         <a class="drug drug_general" data-topicid="9418" href="/z/d/drug information/9418.html" rel="external">
          Erythromycin
         </a>
         Study (BLESS) randomly assigned 117 patients with two or more exacerbations of noncystic fibrosis bronchiectasis in the prior year to take erythromycin 400 mg or placebo twice daily for one year [
         <a href="#rid47">
          47
         </a>
         ]. Protocol defined pulmonary exacerbations were modestly reduced in the erythromycin group (mean 1.29 versus 1.97 per patient per year, incidence rate ratio [IRR], 0.57 [95% CI 0.42-0.77]). The volume of sputum produced and rate of decline in forced expiratory volume in one second (FEV
         <sub>
          1
         </sub>
         ) were also decreased, although the clinical importance of these changes appears small. A follow-up study of the sputum microbiota of the 44 subjects in the erythromycin group showed that reduced exacerbations occurred predominantly among subjects with initial dominance of
         <em>
          Pseudomonas
         </em>
         in their sputum [
         <a href="#rid48">
          48
         </a>
         ]. Over the course of the study, erythromycin increased the proportion of macrolide-resistant oropharyngeal streptococci [
         <a href="#rid47">
          47
         </a>
         ]. In addition, those subjects with
         <em>
          Haemophilus
         </em>
         as the primary sputum pathogen had an increased presence of
         <em>
          Pseudomonas
         </em>
         and reduced presence of
         <em>
          Haemophilus
         </em>
         after being on erythromycin for a year [
         <a href="#rid48">
          48
         </a>
         ].
        </p>
        <p>
         Chronic low-dose administration of a macrolide antibiotic appears to have an effect that is not solely antimicrobial [
         <a href="#rid49">
          49
         </a>
         ]. A variety of alternative mechanisms have been proposed to explain the observed benefit, including reduction of biofilm around virulent gram negative organisms such as
         <em>
          P. aeruginosa
         </em>
         , retardation of neutrophilic influx, stabilization of nuclear and cellular membranes, and promotion of gastric emptying that may reduce potential for acid reflux.
        </p>
        <p class="headingAnchor" id="H2256545861">
         <span class="h3">
          Potential adverse effects
         </span>
         <span class="headingEndMark">
          —
         </span>
         The impact of adverse effects, such as gastrointestinal symptoms, hepatotoxicity, decreased hearing, and increased bacterial resistance, will need ongoing review and attention. In addition, macrolide antibiotics are associated with the potential for prolongation of the QT interval. Clinicians should assess the risk of torsades de pointes when considering a macrolide for long-term treatment in patients at risk for cardiovascular events. Patients at particular risk include those with existing QT interval prolongation, hypokalemia, hypomagnesemia, significant bradycardia, bradyarrhythmias, uncompensated heart failure, and those receiving certain antiarrhythmic drugs. (See
         <a class="medical medical_review" href="/z/d/html/474.html" rel="external">
          "Azithromycin and clarithromycin", section on 'QT interval prolongation and cardiovascular events'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H3711898063">
         <span class="h2">
          Nonmacrolide oral antibiotics
         </span>
         <span class="headingEndMark">
          —
         </span>
         Daily oral nonmacrolide antibiotic treatment has been studied in small case series, but not randomized trials. Based on clinical experience, we usually reserve daily suppressive nonmacrolide antibiotic regimens (eg,
         <a class="drug drug_general" data-topicid="8673" href="/z/d/drug information/8673.html" rel="external">
          amoxicillin
         </a>
         500 mg twice daily,
         <a class="drug drug_general" data-topicid="9393" href="/z/d/drug information/9393.html" rel="external">
          doxycycline
         </a>
         100 mg twice daily) for patients with three or more exacerbations a year who are not candidates for long-term macrolide administration and do not have airway infection with
         <em>
          P. aeruginosa
         </em>
         [
         <a href="#rid50">
          50
         </a>
         ]. Patients who have chronic airway infection with
         <em>
          P. aeruginosa
         </em>
         may be candidates for inhaled antibiotic therapy, as described below. (See
         <a class="local">
          'Inhaled antibiotics'
         </a>
         below.)
        </p>
        <p class="headingAnchor" id="H758640554">
         <span class="h2">
          Inhaled antibiotics
         </span>
         <span class="headingEndMark">
          —
         </span>
         In accordance with society guidelines and systematic reviews, we suggest a therapeutic trial of inhaled antibiotics for patients with
         <em>
          P. aeruginosa
         </em>
         in their sputum and either three or more exacerbations per year or significant morbidity from fewer exacerbations [
         <a href="#rid2">
          2,37,51,52
         </a>
         ]. Additionally, treatment with inhaled antibiotics may be reasonable for patients not infected with
         <em>
          P. aeruginosa
         </em>
         in whom oral antibiotic prophylaxis is contraindicated, not tolerated, or ineffective [
         <a href="#rid2">
          2
         </a>
         ]. Combination therapy with an inhaled antibiotic and a macrolide is typically not useful but may be attempted if single-agent treatment has been only marginally effective. (See
         <a class="local">
          'Macrolides'
         </a>
         above.)
        </p>
        <p>
         Our first choice for patients with &gt;2 to 3 exacerbations/year and sputum growing a Gram negative potential pathogen is one of the commercially available inhaled
         <a class="drug drug_general" data-topicid="10000" href="/z/d/drug information/10000.html" rel="external">
          tobramycin
         </a>
         agents. For individuals who cannot tolerate tobramycin, inhaled
         <a class="drug drug_general" data-topicid="9047" href="/z/d/drug information/9047.html" rel="external">
          aztreonam
         </a>
         ,
         <a class="drug drug_general" data-topicid="8718" href="/z/d/drug information/8718.html" rel="external">
          colistin
         </a>
         , or
         <a class="drug drug_general" data-topicid="8489" href="/z/d/drug information/8489.html" rel="external">
          gentamicin
         </a>
         are possible choices. Aerosolized preparations of aztreonam lysine and colistin have demonstrated benefit in CF, but not in noncystic fibrosis bronchiectasis, possibly due to methodologic issues. Inhaled aztreonam lysine is available and widely used in CF. Inhaled colistin and gentamicin are used in Europe, but commercial products are not available in the United States. No formulation of inhaled
         <a class="drug drug_general" data-topicid="9267" href="/z/d/drug information/9267.html" rel="external">
          ciprofloxacin
         </a>
         is available specifically for inhalation (see
         <a class="local">
          'Ineffective agents'
         </a>
         below).
        </p>
        <p>
         Inhaled antibiotics (eg,
         <a class="drug drug_general" data-topicid="10000" href="/z/d/drug information/10000.html" rel="external">
          tobramycin
         </a>
         ,
         <a class="drug drug_general" data-topicid="9047" href="/z/d/drug information/9047.html" rel="external">
          aztreonam
         </a>
         ,
         <a class="drug drug_general" data-topicid="8718" href="/z/d/drug information/8718.html" rel="external">
          colistin
         </a>
         ) have been investigated primarily in patients with cystic fibrosis when
         <em>
          P. aeruginosa
         </em>
         is present in the respiratory secretions. Benefits in these patients include reduced sputum
         <em>
          Pseudomonas
         </em>
         density, improved FEV
         <sub>
          1
         </sub>
         , and decreased hospitalizations. Inhaled antibiotics may play a role in the management of some patients with noncystic fibrosis bronchiectasis and
         <em>
          Pseudomonas
         </em>
         colonization, but no agent is approved for this purpose by the US Food and Drug Administration (FDA). (See
         <a class="medical medical_review" href="/z/d/html/6371.html" rel="external">
          "Cystic fibrosis: Antibiotic therapy for chronic pulmonary infection", section on 'Inhaled antibiotics'
         </a>
         .)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Inhaled
         </strong>
         <a class="drug drug_general" data-topicid="10000" href="/z/d/drug information/10000.html" rel="external">
          tobramycin
         </a>
         – Tobramycin is available for inhalation as a solution for nebulization and in a dry powder inhaler [
         <a href="#rid53">
          53-58
         </a>
         ]. The usual dose for nebulization is 300 mg/5 mL every 12 hours in repeated cycles of 28 days on the drug followed by 28 days off. The powdered form is dosed 112 mg (4 capsules of 28 mg each) every 12 hours in the same 28-day repeated cycles [
         <a href="#rid54">
          54
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         In a systematic review, five studies (184 participants) were identified that compared nebulized
         <a class="drug drug_general" data-topicid="10000" href="/z/d/drug information/10000.html" rel="external">
          tobramycin
         </a>
         with placebo in patients with bronchiectasis and
         <em>
          P. aeruginosa
         </em>
         [
         <a href="#rid53">
          53
         </a>
         ]. Inhaled tobramycin reduced
         <em>
          P. aeruginosa
         </em>
         density in sputum. Improvements in patient-important outcomes such as hospitalizations, exacerbations, and symptoms had a positive trend, but definitive conclusions were limited by variable study designs and small numbers.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         A larger trial of standard-dose inhaled
         <a class="drug drug_general" data-topicid="10000" href="/z/d/drug information/10000.html" rel="external">
          tobramycin
         </a>
         versus placebo in patients with bronchiectasis and chronic
         <em>
          P. aeruginosa
         </em>
         infection demonstrated similar reductions in pseudomonas density (mean 1.74 Log
         <sub>
          10
         </sub>
         colony forming units/g) as well as a borderline clinically meaningful improvement in respiratory symptoms (Quality of Life-Bronchiectasis Respiratory Symptom Score; +7.9) [
         <a href="#rid59">
          59
         </a>
         ]. These changes modestly diminished over additional treatment cycles. There were no statistically significant differences in lung function or exacerbation rates.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Aerosolized
         </strong>
         <a class="drug drug_general" data-topicid="9047" href="/z/d/drug information/9047.html" rel="external">
          aztreonam
         </a>
         <strong>
          lysine
         </strong>
         – Aztreonam is a monobactam with a monocyclic beta-lactam structure. Aerosolized aztreonam lysine is used in patients with CF in whom inhaled
         <a class="drug drug_general" data-topicid="10000" href="/z/d/drug information/10000.html" rel="external">
          tobramycin
         </a>
         is not effective or not well tolerated, but it is off label in noncystic fibrosis bronchiectasis. The lysine salt formulation is used for inhalation instead of the intravenous preparation, which induces airway inflammation. The dose is 75 mg via eFlow mesh nebulizer three times daily in repeated cycles of 28 days on drug followed by 28 days off drug. Pretreatment with a bronchodilator is advised. (See
         <a class="medical medical_review" href="/z/d/html/6371.html" rel="external">
          "Cystic fibrosis: Antibiotic therapy for chronic pulmonary infection", section on 'Inhaled aztreonam lysine'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/552.html" rel="external">
          "Delivery of inhaled medication in adults", section on 'Mesh nebulizers'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         In paired trials (AIR-BX1 and AIR-BX2) that included a total of 540 patients with bronchiectasis and positive respiratory cultures for Gram negative organisms, inhaled
         <a class="drug drug_general" data-topicid="9047" href="/z/d/drug information/9047.html" rel="external">
          aztreonam
         </a>
         did not result in clinically significant improvement in respiratory quality of life after four weeks, despite some benefit being demonstrated in separate studies of patients with cystic fibrosis and
         <em>
          Pseudomonas
         </em>
         airway colonization [
         <a href="#rid60">
          60
         </a>
         ]. A “second” look at the data from this study showed that the individuals with higher bacterial load (all screening cultures had quantitative analysis of bacterial organisms) of the pathogenic organisms showed an improvement in the respiratory domain of the QOL-B questionnaire as compared to those with a lower bacterial load [
         <a href="#rid61">
          61
         </a>
         ]. In a retrospective analysis of 440 participants in AIR-BX1 and AIR-BX2, cough and purulence (evidence by color) were significantly improved with aztreonam compared with placebo [
         <a href="#rid62">
          62
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         An additional clinical trial of
         <a class="drug drug_general" data-topicid="9047" href="/z/d/drug information/9047.html" rel="external">
          aztreonam
         </a>
         lysine in noncystic fibrosis bronchiectasis is in progress (
         <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fclassic.clinicaltrials.gov%2Fct2%2Fshow%2FNCT03696290%3Fterm%3Daztreonam%26cond%3DBronchiectasis%26draw%3D2%26rank%3D1&amp;token=bSACj8jvIPbAsdLszaS25zlk292wBF34Bhviwjb%2B9LAQvpG54cuOXDuhWvq3%2F%2B23%2Fj0l0QBMRgP9yf8vho4zY8Cj0XIZBKYEEZPzXgACpJ532%2FqHziwJqWrEtuTcYHYtGYkfnHAi88GNUzYxERMlzg%3D%3D&amp;TOPIC_ID=129310" target="_blank">
          NCT03696290
         </a>
         ).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Aerosolized
         </strong>
         <a class="drug drug_general" data-topicid="8718" href="/z/d/drug information/8718.html" rel="external">
          colistin
         </a>
         – Inhaled colistin (colistimethate) is used to treat chronic
         <em>
          P. aeruginosa
         </em>
         infection in CF. In the United States, it is delivered by nebulizing an intravenous formulation (an off-label use). Outside of the United States, formulations designed for inhalation are available, either as a powder intended for suspension in liquid and nebulization, or as capsules containing a dry powder that is directly inhaled. The dose typically used in CF is 150 mg, diluted in 2 mL of sterile water and administered by nebulizer twice per day for 28 days, alternating with 28 days off treatment.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         A randomized trial of inhaled
         <a class="drug drug_general" data-topicid="8718" href="/z/d/drug information/8718.html" rel="external">
          colistin
         </a>
         1 million IU (aerosolized via I-neb) versus
         <a class="drug drug_general" data-topicid="9929" href="/z/d/drug information/9929.html" rel="external">
          saline
         </a>
         placebo was performed in 144 subjects with
         <em>
          P. aeruginosa
         </em>
         in their sputum (phase 2). Each subject received two weeks of intravenous anti-pseudomonal antibiotics for an exacerbation before enrollment. The median time to first exacerbation was not significantly different (p = 0.11) in the colistin subjects (165 days) compared with the placebo subjects (111 days). Secondary endpoints that favored colistin were improved QOL and reduced bacterial sputum density of
         <em>
          Pseudomonas
         </em>
         (similar to most other aerosol antibiotic trials) [
         <a href="#rid63">
          63
         </a>
         ]. A preliminary report on a phase 3 trial (PROMIS-I) of inhaled colistin reported reduced exacerbations, prolonged time to first exacerbation, and reduced levels of
         <em>
          P. aeruginosa
         </em>
         in sputum [
         <a href="#rid64">
          64
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/6371.html" rel="external">
          "Cystic fibrosis: Antibiotic therapy for chronic pulmonary infection", section on 'Inhaled colistin'
         </a>
         .)
        </p>
        <p>
        </p>
        <p>
         Studies have not demonstrated benefit with inhaled
         <a class="drug drug_general" data-topicid="9267" href="/z/d/drug information/9267.html" rel="external">
          ciprofloxacin
         </a>
         or inhaled
         <a class="drug drug_general" data-topicid="8489" href="/z/d/drug information/8489.html" rel="external">
          gentamicin
         </a>
         for noncystic fibrosis bronchiectasis, although inhaled gentamicin is used in some countries. Inhaled ciprofloxacin is discussed below. (See
         <a class="local">
          'Ineffective agents'
         </a>
         below.)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Aerosolized
         </strong>
         <a class="drug drug_general" data-topicid="8489" href="/z/d/drug information/8489.html" rel="external">
          gentamicin
         </a>
         – Aerosolized gentamicin, prepared by diluting the intravenous preparation with
         <a class="drug drug_general" data-topicid="9929" href="/z/d/drug information/9929.html" rel="external">
          saline
         </a>
         , was assessed in 58 patients with noncystic fibrosis bronchiectasis, who were randomly assigned to use nebulized gentamicin 80 mg twice daily or normal saline placebo for a year [
         <a href="#rid65">
          65
         </a>
         ]. Patients were aware of their medication assignment. The primary endpoint of reduction in sputum bacterial density was achieved in the gentamicin cohort as compared with no reduction in the saline group. Thirty-one percent of the gentamicin cohort had complete eradication of
         <em>
          Pseudomonas
         </em>
         at the end of 12 months. Favorable secondary endpoints in subjects taking gentamicin included reduction in exacerbations and improved patient outcomes by analysis of two questionnaires. However, no differences were seen in the 24-hour sputum volume or in spirometric parameters. In addition, the sputum bacterial density was no longer different from control at the three-month follow-up visit. Further study is needed before routine use of nebulized intravenous gentamicin can be recommended.
        </p>
        <p>
        </p>
        <p>
         All of the inhaled antibiotics have the potential to cause bronchospasm, so the first treatment is generally administered in a supervised setting with spirometry before and 15 and 30 minutes after the test dose [
         <a href="#rid50">
          50
         </a>
         ]. If a patient is likely to develop bronchospasm, it will usually occur during the first treatment.
         <a class="drug drug_general" data-topicid="9396" href="/z/d/drug information/9396.html" rel="external">
          Albuterol
         </a>
         should be immediately available for inhalation should bronchospasm develop. Subsequently, pretreatment with an inhaled beta-agonist bronchodilator can be given to those patients who develop mild bronchoconstriction. For those whose FEV
         <sub>
          1
         </sub>
         decreases by &gt;15 percent or &gt;200 mL after antibiotic inhalation, we generally do not administer further doses.
        </p>
        <p>
         Patients treated with inhaled antibiotics should be assessed for medication-related adverse effects (eg, throat irritation or pain, abnormal taste sensation, cough, chest discomfort) and development of resistant organisms.
        </p>
        <p class="headingAnchor" id="H98220367">
         <span class="h2">
          Intermittent intravenous antibiotics
         </span>
         <span class="headingEndMark">
          —
         </span>
         Intermittent intravenous antibiotics are not part of routine care of patients with stable bronchiectasis. In the absence of an acute exacerbation, administration of intravenous antibiotics should be reserved for patients with resistant organisms (such as
         <em>
          Pseudomonas
         </em>
         ) being prepared for major surgery, such as resection of a bronchiectatic region of lung or another procedure during which pulmonary function may be compromised.
        </p>
        <p class="headingAnchor" id="H3289536470">
         <span class="h2">
          Eradication of new isolates of Pseudomonas
         </span>
         <span class="headingEndMark">
          —
         </span>
         The ERS guidelines suggest eradication of new
         <em>
          P. aeruginosa
         </em>
         infection, but note that data are limited [
         <a href="#rid2">
          2
         </a>
         ]. Other experts, including ourselves, do not use eradication regimens in this setting due to the small number of patients studied and unclear benefit.
        </p>
        <p>
         Studies in support of eradication of new
         <em>
          P. aeruginosa
         </em>
         isolates include the following:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         In a randomized trial, 35 patients with new
         <em>
          P. aeruginosa
         </em>
         isolation were assigned to
         <a class="drug drug_general" data-topicid="9226" href="/z/d/drug information/9226.html" rel="external">
          ceftazidime
         </a>
         and
         <a class="drug drug_general" data-topicid="10000" href="/z/d/drug information/10000.html" rel="external">
          tobramycin
         </a>
         intravenously followed by nebulized tobramycin 300 mg twice daily or placebo for three months [
         <a href="#rid58">
          58
         </a>
         ]. Twelve months later, 54 percent of the eradication group and 29 percent of the placebo group were free of
         <em>
          P. aeruginosa
         </em>
         in sputum cultures. The eradication group had fewer exacerbations, hospital admissions, and hospital days during follow-up.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         A retrospective study of 30 patients who underwent eradication therapy with a variety of regimens had a reduction in exacerbation frequency following eradication, but only 54 percent were free of
         <em>
          P. aeruginosa
         </em>
         after a median follow-up of 26 months [
         <a href="#rid66">
          66
         </a>
         ].
        </p>
        <p>
        </p>
        <p>
         Eradication of chronic
         <em>
          P. aeruginosa
         </em>
         infection (present for years) is unlikely to be successful [
         <a href="#rid2">
          2
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H1547647953">
         <span class="h1">
          OTHER MEDICAL THERAPIES
         </span>
         <span class="headingEndMark">
          —
         </span>
         Other potential, but less well-studied, therapies for bronchiectasis, include inhaled bronchodilators, anti-inflammatory medications, anti-gastroesophageal reflux therapies, and immunization.
        </p>
        <p class="headingAnchor" id="H222951283">
         <span class="h2">
          Bronchodilators
         </span>
         <span class="headingEndMark">
          —
         </span>
         Airway reactivity, presumably due to transmural inflammation, is often present in patients with bronchiectasis. However, aerosol bronchodilator therapy, as used in asthma and COPD, has not been studied extensively in bronchiectasis.
        </p>
        <p>
         When deciding whether to prescribe a bronchodilator for bronchiectasis, we usually assess airflow obstruction on spirometry before and after bronchodilator.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         For those patients with bronchodilator reversibility, we typically initiate a trial of a short-acting beta-agonist [
         <a href="#rid50">
          50
         </a>
         ]. If symptoms improve on therapy, either a short- or long-acting beta-agonist is continued.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         For those lacking evidence of airway obstruction on spirometry, we typically do not initiate long-acting bronchodilators.
        </p>
        <p>
        </p>
        <p>
         In an unblinded trial of patients with bronchiectasis and airway obstruction, the combination of inhaled
         <a class="drug drug_general" data-topicid="8946" href="/z/d/drug information/8946.html" rel="external">
          formoterol
         </a>
         with
         <a class="drug drug_general" data-topicid="9167" href="/z/d/drug information/9167.html" rel="external">
          budesonide
         </a>
         640 mcg/day was compared with inhaled budesonide 1600 mcg/day alone [
         <a href="#rid67">
          67,68
         </a>
         ]. The formoterol group experienced improved dyspnea, coughing, and health related quality of life (HRQL) based on a questionnaire (St. George's respiratory questionnaire [SGRQ]-Spanish version) without alteration in sputum pathogens or an increase in adverse effects.
        </p>
        <p>
         In a small placebo-controlled trial of 34 patients with bronchiectasis without reversible airway obstruction, COPD, or asthma, beclomethasone-formoterol combination therapy showed no effect on cough, quality of life, dyspnea, lung function, or pulmonary exacerbations [
         <a href="#rid69">
          69
         </a>
         ]. However, more adverse events (including exacerbations) and therapeutic discontinuation occurred in the ICS/LABA group.
        </p>
        <p>
         There is little evidence to suggest that LAMAs improve patient-important outcomes in patients with bronchiectasis. One double-blind cross-over trial assessed the use of
         <a class="drug drug_general" data-topicid="10300" href="/z/d/drug information/10300.html" rel="external">
          tiotropium
         </a>
         in patients with noncystic fibrosis bronchiectasis, airflow obstruction, and a &lt;20 pack-year smoking history [
         <a href="#rid70">
          70
         </a>
         ]. Approximately half of the patients were on treatment with long-acting beta-agonist/inhaled glucocorticoid therapy, which was maintained throughout the trial. After 26 weeks, tiotropium modestly improved trough FEV
         <sub>
          1
         </sub>
         (treatment difference 58 mL [3.3 percent], 95% CI 23-92 mL), but failed to impact exacerbation rate, patient-centered measures of disease, or sputum neutrophil or eosinophil counts. The patients were not stratified by bronchodilator responsiveness.
        </p>
        <p>
         Further study is needed before long-acting bronchodilators are used routinely in patients with bronchiectasis who lack wheezing or reversible airflow limitation.
        </p>
        <p class="headingAnchor" id="H3722466793">
         <span class="h2">
          Anti-inflammatory medications
         </span>
         <span class="headingEndMark">
          —
         </span>
         Since inflammation and neutrophilic mediator release play a major role in bronchiectasis, anti-inflammatory agents such as oral or inhaled glucocorticoids, nonsteroidal anti-inflammatory agents (NSAIDs), and statins might theoretically be beneficial. However, there are no large randomized trials that support efficacy of any of these agents in adults with stable or acute bronchiectasis, and we do not use NSAIDs or statins for this purpose. (See
         <a class="local">
          'Ineffective agents'
         </a>
         below.)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Oral glucocorticoids
         </strong>
         – We reserve systemic glucocorticoids for acute exacerbations of bronchiectasis that are accompanied by wheezing suggestive of concomitant asthma or allergic bronchopulmonary aspergillosis. In other patients, systemic glucocorticoids are avoided because they depress host immunity, promote bacterial and fungal colonization, and may perpetuate infection. In addition, oral glucocorticoids have other significant adverse effects that are discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/7988.html" rel="external">
          "Major adverse effects of systemic glucocorticoids"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Inhaled glucocorticoids
         </strong>
         – Current evidence is insufficient to support routine inhaled glucocorticoid therapy for patients with bronchiectasis but without concomitant asthma or COPD [
         <a href="#rid50">
          50,71
         </a>
         ], and ERS guidelines advise against use of inhaled glucocorticoid therapy in the absence of asthma or COPD [
         <a href="#rid2">
          2
         </a>
         ]. A systematic review of seven randomized trials with a total of 380 participants did not find a significant difference in spirometry, exacerbation rate, or sputum volume between patients using inhaled glucocorticoids and those on placebo [
         <a href="#rid71">
          71
         </a>
         ]. In contrast, a post hoc analysis of a study of inhaled glucocorticoids in bronchiectasis (published after the systematic review) suggested that individuals with blood eosinophils &gt;3 percent had improved QOL by the SGRQ at the end of six months compared with those who did not use inhaled glucocorticoids or had lower eosinophil counts [
         <a href="#rid72">
          72
         </a>
         ]. Similarly, a separate registry analysis of 928 patients with bronchiectasis (but not asthma or allergic bronchopulmonary aspergillosis) examined bronchiectasis outcomes according to degree of peripheral eosinophilia [
         <a href="#rid73">
          73
         </a>
         ]. Inhaled glucocorticoids only showed a significant impact on exacerbations in the subgroup with peripheral eosinophil counts &gt;300 cells/microL (n = 153), in which those taking glucocorticoids had decreased total exacerbations (1.5 versus 2.2 per year) and hospitalizations (0.7 versus 1.2 per year) compared with the entire cohort. Further study on inhaled glucocorticoids in those with elevated markers of type 2 inflammation may better define a therapeutic role for these agents in bronchiectasis.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Inhaled glucocorticoids have potential adverse effects. A registry study found that inhaled glucocorticoid use was associated with a greater likelihood of
         <em>
          Pseudomonas aeruginosa
         </em>
         infection (adjusted odds ratio 1.8 [95% CI 1.24-2.6]), although it is not possible to determine causality from the available data [
         <a href="#rid74">
          74
         </a>
         ]. A separate study found evidence of adrenal insufficiency in 48 percent of patients with bronchiectasis who were taking inhaled glucocorticoids and in 23 percent of those not using inhaled glucocorticoids [
         <a href="#rid75">
          75
         </a>
         ]. Adverse effects of inhaled glucocorticoids are discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/540.html" rel="external">
          "Major side effects of inhaled glucocorticoids"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H1389996380">
         <span class="h2">
          Gastroesophageal reflux
         </span>
         <span class="headingEndMark">
          —
         </span>
         There is emerging concern that gastroesophageal reflux (GER) and bronchiectasis are associated [
         <a href="#rid76">
          76,77
         </a>
         ]. Among patients with advanced lung disease awaiting lung transplantation, patients with bronchiectasis had the highest prevalence of GER (50 percent) [
         <a href="#rid78">
          78
         </a>
         ]. In a retrospective series of 81 patients with bronchiectasis from a single center in Ireland, 36 percent had a hiatal hernia and 62 percent had symptomatic GER. Although there was no predilection for a single lobe to be involved with bronchiectasis, bronchiectasis severity scores were higher or more severe in the hiatal hernia subjects [
         <a href="#rid79">
          79
         </a>
         ]. As a result, gastric acid suppression (eg, H2 blocker, proton pump inhibitor) is used in patients with symptomatic GER or those with two or more exacerbations in a year. The role of diagnostic testing (eg, esophageal pH monitoring, manometry, esophagram, or upper endoscopy) is uncertain. We typically pursue diagnostic testing or additional anti-reflux measures in patients with persistent symptoms or frequent, unexplained exacerbations. (See
         <a class="medical medical_review" href="/z/d/html/2265.html" rel="external">
          "Clinical manifestations and diagnosis of gastroesophageal reflux in adults"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/2258.html" rel="external">
          "Medical management of gastroesophageal reflux disease in adults"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H3582390248">
         <span class="h2">
          Immunizations
         </span>
         <span class="headingEndMark">
          —
         </span>
         Data are limited regarding immunization guidelines for individuals with bronchiectasis.
        </p>
        <p>
         Seasonal influenza vaccine is administered annually to patients with bronchiectasis,
         <strong>
          except
         </strong>
         those unable to receive live attenuated vaccines due to immune deficiency disease  (
         <a class="graphic graphic_table graphicRef110756" href="/z/d/graphic/110756.html" rel="external">
          table 5
         </a>
         ). (See
         <a class="medical medical_review" href="/z/d/html/7007.html" rel="external">
          "Seasonal influenza vaccination in adults"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/106521.html" rel="external">
          "Immunizations in patients with inborn errors of immunity"
         </a>
         .)
        </p>
        <p>
         Pneumococcal vaccine is typically given to patients with bronchiectasis, as is recommended for patients with other chronic respiratory diseases [
         <a href="#rid80">
          80
         </a>
         ]. Pneumococcal vaccination with the conjugate vaccine is recommended for patients with combined immunodeficiencies, antibody deficiency, complement deficiencies, congenital asplenia, and phagocyte disorders who are not receiving
         <a class="drug drug_general" data-topicid="16471" href="/z/d/drug information/16471.html" rel="external">
          immune globulin
         </a>
         (
         <a class="graphic graphic_table graphicRef110756" href="/z/d/graphic/110756.html" rel="external">
          table 5
         </a>
         ). In a randomized trial of 167 adults with chronic respiratory diseases including 20 with probable bronchiectasis, the group receiving both influenza and pneumococcal vaccines had significantly reduced numbers of acute infectious exacerbations during the first, but not second year of the study as compared to the group receiving the influenza vaccine alone [
         <a href="#rid81">
          81
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/7021.html" rel="external">
          "Pneumococcal vaccination in adults"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/106521.html" rel="external">
          "Immunizations in patients with inborn errors of immunity", section on 'Pneumococcal vaccine'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H1296026968">
         <span class="h2">
          Ineffective agents
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Inhaled
         </strong>
         <a class="drug drug_general" data-topicid="9267" href="/z/d/drug information/9267.html" rel="external">
          ciprofloxacin
         </a>
         – Studies of the efficacy of inhaled ciprofloxacin have yielded mixed results, and there is no formulation that is licensed for clinical use.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         In the first of two identical randomized trials, RESPIRE 1, 416 subjects with bronchiectasis were assigned to a dry powder formulation of
         <a class="drug drug_general" data-topicid="9267" href="/z/d/drug information/9267.html" rel="external">
          ciprofloxacin
         </a>
         32.5 mg twice daily for 14 days on/off, 28 days on/off, or placebo [
         <a href="#rid82">
          82
         </a>
         ]. Ciprofloxacin in the 14 day on/off regimen resulted in a significantly prolonged time to first exacerbation median time &gt;336 versus 186 days (hazard ratio 0.53, 97.5% CI 0.36–0.80) and reduced frequency of exacerbations compared with placebo in the 14 day on/off regimen (incidence rate ratio 0.61, 97.5% CI 0.40–0.91), but not the 28 day on/off regimen [
         <a href="#rid82">
          82
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         In two separate trials (identical protocols) of aerosolized liposomal
         <a class="drug drug_general" data-topicid="9267" href="/z/d/drug information/9267.html" rel="external">
          ciprofloxacin
         </a>
         (135 mg liposome encapsulated plus 54 mg of free ciprofloxacin; called ARD-3150), participants (290 in ORBIT-3 and 308 in ORBIT-4) were randomly assigned (2:1) to ciprofloxacin or placebo once daily for 48 weeks [
         <a href="#rid83">
          83
         </a>
         ]. The primary endpoint, median time to first exacerbation, was significantly prolonged in the ARD-3150 group in ORBIT-4, but not in ORBIT-3 nor the pooled groups. There was no difference in adverse events between ARD-3150 and placebo.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          NSAIDs
         </strong>
         – Oral
         <a class="drug drug_general" data-topicid="8547" href="/z/d/drug information/8547.html" rel="external">
          ibuprofen
         </a>
         is occasionally used to reduce airway inflammation in children aged 6 to 13 with cystic fibrosis, but data are insufficient to support a role for oral or inhaled NSAIDs in adult noncystic fibrosis bronchiectasis [
         <a href="#rid84">
          84,85
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/6372.html" rel="external">
          "Cystic fibrosis: Overview of the treatment of lung disease", section on 'Ibuprofen'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Statins
         </strong>
         – Statins have anti-inflammatory properties, but preliminary data do not support a role in bronchiectasis unless the patient has another indication for statin therapy. In a pilot, single-center study, 60 subjects with stable, mild bronchiectasis were administered
         <a class="drug drug_general" data-topicid="8949" href="/z/d/drug information/8949.html" rel="external">
          atorvastatin
         </a>
         80 mg or placebo daily for six months [
         <a href="#rid86">
          86
         </a>
         ]. Scores on the Leicester Cough Questionnaire (LCQ) were significantly improved by 1.5 units (1.3 units is minimum clinically important difference) in the atorvastatin group as compared with -0.7 units in the placebo group. Adverse events including headache, leg pain, and diarrhea were more frequent in the atorvastatin group.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         In a randomized, crossover study of 32 patients with severe bronchiectasis and chronic
         <em>
          Pseudomonas aeruginosa
         </em>
         in their sputum, 27 completed the six-month trial (three months on
         <a class="drug drug_general" data-topicid="8949" href="/z/d/drug information/8949.html" rel="external">
          atorvastatin
         </a>
         80 mg daily or placebo) [
         <a href="#rid87">
          87
         </a>
         ]. Cough as measured by the LCQ (primary endpoint) did not improve on atorvastatin. There was improvement in the SGRQ and some indices of systemic inflammation.
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H3823822010">
         <span class="h1">
          PHYSICIAN-PATIENT PARTNERSHIP
         </span>
         <span class="headingEndMark">
          —
         </span>
         Bronchiectasis is a chronic disease that requires prompt responses to exacerbations and, for many patients, daily therapy at home. Partnerships between patients and the clinical team (physicians, nurses, respiratory therapists, pharmacists) are essential to the development of successful management plans and reinforcement of treatment modalities [
         <a href="#rid88">
          88
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H292110435">
         <span class="h2">
          Collaborative management
         </span>
         <span class="headingEndMark">
          —
         </span>
         We establish an active partnership with patients to identify goals that are important (eg, reducing and expectorating sputum, maintaining and improving exercise tolerance, treating bacterial infections promptly, and avoiding hospitalization) and work with them to achieve these goals. Patients are more likely to adhere to therapies that resonate with their goals when they participate in the decision-making. The physician/health care provider acts as an educator and facilitator.
        </p>
        <p>
         The British Thoracic Society advises use of a bronchiectasis self-management plan [
         <a href="#rid89">
          89,90
         </a>
         ], although formal research in support of self-management in bronchiectasis is limited. A systematic review found two trials that assessed self-management interventions for bronchiectasis; neither met the primary end-point of improved health-related quality of life.
        </p>
        <p class="headingAnchor" id="H2710059462">
         <span class="h2">
          Education and self-efficacy
         </span>
         <span class="headingEndMark">
          —
         </span>
         Patients have a spectrum of learning styles and literacy skills, so programs should provide patients with a variety of resources to help match their individual needs. Video and electronic communication and patient-driven resources are important adjuncts to office explanations (
         <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fbronchiectasis.azurewebsites.net%2F&amp;token=yiml3%2B%2BT9PZrHArVlLsjENak9wXlpK622eiDkGxg8np9sHuRBCvn7Ebplx%2BwqkAcZsUo3ioTEEd10ZhXqk0vHA%3D%3D&amp;TOPIC_ID=129310" target="_blank">
          www.bronchiectasis.me
         </a>
         ) [
         <a href="#rid88">
          88
         </a>
         ]. (See
         <a class="local">
          'Information for patients'
         </a>
         below.)
        </p>
        <p>
         The key educational topics include the meaning of the diagnosis of “bronchiectasis,” why patients develop it, what symptoms they can expect to have in the future, how they can adjust their day-to-day activities to minimize disease impact, and how best to respond to early symptoms of an exacerbation. Armed with this information, patients can develop self-efficacy and take an active role in management of their bronchiectasis.
        </p>
        <p class="headingAnchor" id="H3714050300">
         <span class="h2">
          Communication
         </span>
         <span class="headingEndMark">
          —
         </span>
         Communication between the healthcare team and the patient is enhanced by an understanding of the individual patient’s disease experience and how they engage with information about their health. Eliciting and responding to the patient’s concerns and questions helps to build trust and providing educational resources that dovetail with the advice given by the healthcare team can increase that trust [
         <a href="#rid9">
          9
         </a>
         ]. A written management plan should be prepared, reviewed, and edited over time as needed. Communication channels should be made clear (ie, phone numbers for general and emergency use, access to secure electronic messaging, names of primary caregiver and/or consultants, and resources for emergency care [emergency department, Urgent Care, etc]).
        </p>
        <p class="headingAnchor" id="H1905798204">
         <span class="h2">
          Monitoring
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Symptoms and history
         </strong>
         – Patients should be asked about dyspnea and exercise tolerance. Color, consistency, and estimated quantity of sputum should be recorded at each visit as this information is helpful when determining if a patient has an exacerbation. New or increasing hemoptysis is almost always a concern for medical attention.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Between visits, patients should record exacerbations particularly when they’ve had an emergency department visit or hospitalization, or antibiotics have been administered.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         New respiratory medications including dosage and frequency should be recorded and shared. Use of airway clearance techniques should be reviewed. Personal exercise programs should be updated (walking, treadmill/cycle, etc) along with any limitations.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Sputum culture
         </strong>
         – Sputum culture is obtained at the time of exacerbations before administration of an antibiotic and periodically at the time of office visits. A sterile sputum collection cup can be provided to the patient to obtain a first morning sample at the time of their next visit or if they have symptoms of an exacerbation.
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H968176584">
         <span class="h1">
          PROGNOSIS
         </span>
         <span class="headingEndMark">
          —
         </span>
         A few studies have examined the frequency of exacerbations, hospitalizations, comorbidities, and mortality, and also the rate of lung function decline among patients with bronchiectasis, although long-term outcomes studies are limited [
         <a href="#rid20">
          20,40,91-95
         </a>
         ].
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Exacerbations
         </strong>
         – Among 1826 patients enrolled in the US Bronchiectasis Research Registry, exacerbations were reported at baseline in 64 percent within the preceding two years [
         <a href="#rid29">
          29
         </a>
         ]. Some patients appear to be “frequent exacerbators” with three or more exacerbations per year, while other patients have fewer exacerbations [
         <a href="#rid96">
          96
         </a>
         ]. In the EMBRACE trial described above, patients with a history of at least one exacerbation in the prior year, the exacerbation rate was 1.57 per patient over 6 months [
         <a href="#rid42">
          42
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Severity and prognosis
         </strong>
         – Scoring systems have been proposed to help guide assessment of prognosis and identify patients who frequently exacerbate [
         <a href="#rid95">
          95,97
         </a>
         ]. The
         <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fbronchiectasis.com.au%2Fassessment%2Fmedical%2Fbronchiectasis-severity-index&amp;token=UYnVs9lPROEB824mIO%2FWpPuwoe3gIBch%2BhJrcZOiSdjO5Ksesn6ExZpcBwwpmCsLeKH2q2rXueqy3jZMGKRYXo9naSUXq3BUD5eM5KioyLA%3D&amp;TOPIC_ID=129310" target="_blank">
          Bronchiectasis Severity Index
         </a>
         (BSI) was derived from 608 bronchiectasis patients at a center in Scotland and validated in 597 patients from other centers in the United Kingdom and Europe [
         <a href="#rid95">
          95
         </a>
         ]. Predictors of hospitalizations included previous hospitalization, high dyspnea index, low forced expiratory volume in one second (FEV
         <sub>
          1
         </sub>
         ), presence of Pseudomonas in sputum, and more extensive involvement (&gt;3 lobes) on high resolution computed tomography (HRCT). Mortality correlated with older age, low FEV
         <sub>
          1
         </sub>
         , previous hospitalization, and three or more exacerbations in the year before study.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         The
         <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fbronchiectasis.com.au%2Fassessment%2Fmedical%2Ffaced-score&amp;token=v3CSIhOxFv%2B6m5ultuDz4mulGIb9hg4XUuxiadnJsm4w9%2FJYVzm%2F8CCBiLaq6i4XdViaxw89palKGDG%2FoXVJcA%3D%3D&amp;TOPIC_ID=129310" target="_blank">
          FACED
         </a>
         score (FEV
         <sub>
          1
         </sub>
         , Age, Colonization with
         <em>
          Pseudomonas
         </em>
         , Extended involvement on chest computed tomography [CT], and Dyspnea) was developed in 397 patients of a multicenter cohort of 819 patients from Spain [
         <a href="#rid97">
          97
         </a>
         ]. The ability of the scoring system to predict five-year all-cause mortality was validated in the remaining patients of the same cohort.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         The BSI and FACED were evaluated retrospectively over 19 years regarding mortality estimates in 91 patients followed at the Royal Brompton Hospital, London. Both scores gave equally reliable mortality estimates at five years with the FACED slightly superior at 15 years [
         <a href="#rid98">
          98
         </a>
         ]. Regarding other clinical outcomes, in a further analysis of 1612 subjects from seven European cohorts, the BSI more accurately predicted exacerbations, hospitalizations, respiratory symptoms, and quality of life than the FACED score [
         <a href="#rid99">
          99
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Another approach to estimating exacerbations and survival utilizes the cluster analysis approach as studied in asthma and chronic obstructive pulmonary disease (COPD). Daily sputum production and the presence of
         <em>
          Pseudomonas
         </em>
         or other potential infectious pathogens in sputum culture were the main features linked to quality of life (QOL), inflammatory markers, and clinical outcome at three years [
         <a href="#rid100">
          100
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Hospitalization and mortality
         </strong>
         – Small studies have described mortality rates of 16 to 20 percent over five years, increasing with intensive care unit (ICU) hospitalization and comorbidity. A study from the United Kingdom found that the age-adjusted mortality for adults with bronchiectasis was approximately twice that of the general population, independent of age differences [
         <a href="#rid33">
          33
         </a>
         ]. Two retrospective series assessed outcomes of patients with bronchiectasis admitted to an ICU for respiratory failure for the first time [
         <a href="#rid91">
          91,101
         </a>
         ]. A report of 48 patients from France found 19 percent mortality in the ICU and 40 percent mortality at one year [
         <a href="#rid91">
          91
         </a>
         ]. In a series of 57 patients from Singapore, an overall hospital mortality of 26 percent was reported with no difference whether the patients received noninvasive ventilation or intubation with mechanical ventilation [
         <a href="#rid101">
          101
         </a>
         ]. Severe hypoxemia and higher APACHE II scores were worse prognostic factors. (See
         <a class="medical medical_review" href="/z/d/html/1636.html" rel="external">
          "Noninvasive ventilation in adults with acute respiratory failure: Benefits and contraindications"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         In 2013, analysis from the Intensive Care National Audit and Research Centre in the United Kingdom included 121 ICU admissions for bronchiectasis or 0.1 percent of all ICU admissions. Mortality was 29 percent (18 percent for COPD in same survey) with a median ICU length of stay of three days and hospital stay of 12 days [
         <a href="#rid102">
          102
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         In a series of 245 patients with bronchiectasis followed in Belgium between 2006 and 2013, mortality was 20 percent, increasing to 55 percent among those with COPD [
         <a href="#rid103">
          103
         </a>
         ]. The cause of death was mainly respiratory (58 percent).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Lung function decline
         </strong>
         – Patients with bronchiectasis have a mean annual decline in FEV
         <sub>
          1
         </sub>
         of 50 to 55 mL per year [
         <a href="#rid40">
          40
         </a>
         ]. This is greater than normal individuals (20 to 30 mL per year), but similar to patients with COPD (approximately 60 mL per year). Among patients with bronchiectasis, the decline in FEV
         <sub>
          1
         </sub>
         is most accelerated when
         <em>
          Pseudomonas
         </em>
         colonization, frequent exacerbations, or increased inflammatory markers (eg, C-reactive protein) exist.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Pulmonary vascular disease
         </strong>
         – An observational study evaluated 94 patients with bronchiectasis using echocardiography [
         <a href="#rid92">
          92
         </a>
         ]. There was evidence of pulmonary hypertension (defined as an estimated systolic pulmonary artery pressure &gt;40 mmHg) in 33 percent of patients and right ventricular systolic dysfunction in 13 percent. Both abnormalities were more common among patients with cystic bronchiectasis. Right ventricular dysfunction correlated with a low FEV
         <sub>
          1
         </sub>
         , low diffusing capacity of carbon monoxide (DLCO), hypercarbia, and hypoxemia. Only 15 percent of patients had evidence of left ventricular dysfunction.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Cardiovascular morbidity
         </strong>
         – Respiratory tract infections are associated with increased cardiovascular events (CV: myocardial infarction, stroke) [
         <a href="#rid104">
          104
         </a>
         ]. In an audit of patients with bronchiectasis from primary care practices in the United Kingdom, an increase in CV events was noted in the first 90 days after a respiratory infection (incidence rate ratio [IRR] 1.56, 95% CI 1.20-2.02) with the greatest relative risk in the first three days (IRR 2.73, 95% CI 1.41-5.27), compared with the individual’s baseline risk [
         <a href="#rid105">
          105
         </a>
         ]. In a separate study, bronchiectasis was an independent risk factor for coronary artery disease and stroke after adjustment for age, sex, smoking, and other known risk factors for CV [
         <a href="#rid106">
          106
         </a>
         ]. Serum desmosine, a marker of elastin degradation, may be a marker for cardiovascular and all-cause mortality [
         <a href="#rid107">
          107
         </a>
         ]. Further study is needed to determine the optimal management of these potential comorbidities.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Cancer
         </strong>
         – A study of cancer in hospitalized patients from Taiwan (National Health Insurance Research database) suggested a significantly increased risk of hematologic malignancies and cancers of the lung and esophagus among patients with bronchiectasis compared with an age, time interval, and presence of COPD diagnosis control group [
         <a href="#rid108">
          108
         </a>
         ]. However, information about cigarette smoking, social factors, and environmental factors were not available in the database to enable adjustment for these variables.
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H127437634">
         <span class="h1">
          SOCIETY GUIDELINE LINKS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See
         <a class="medical medical_society_guidelines" href="/z/d/html/116208.html" rel="external">
          "Society guideline links: Bronchiectasis"
         </a>
         and
         <a class="medical medical_society_guidelines" href="/z/d/html/122199.html" rel="external">
          "Society guideline links: Primary ciliary dyskinesia"
         </a>
         and
         <a class="medical medical_society_guidelines" href="/z/d/html/118986.html" rel="external">
          "Society guideline links: Hemoptysis"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H3283665122">
         <span class="h1">
          INFORMATION FOR PATIENTS
         </span>
         <span class="headingEndMark">
          —
         </span>
         UpToDate offers two types of patient education materials, “The Basics” and “Beyond the Basics.” The Basics patient education pieces are written in plain language, at the 5
         <sup>
          th
         </sup>
         to 6
         <sup>
          th
         </sup>
         grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10
         <sup>
          th
         </sup>
         to 12
         <sup>
          th
         </sup>
         grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.
        </p>
        <p>
         Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on “patient info” and the keyword(s) of interest.)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Basics topic (see
         <a class="medical medical_basics" href="/z/d/html/86554.html" rel="external">
          "Patient education: Bronchiectasis in adults (The Basics)"
         </a>
         )
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H249165590">
         <span class="h1">
          SUMMARY AND RECOMMENDATIONS
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Definition
         </strong>
         – Bronchiectasis is a syndrome of chronic cough and viscid sputum production associated with airway dilation and bronchial wall thickening. Exacerbations are usually caused by acute bacterial infections. (See
         <a class="medical medical_review" href="/z/d/html/1435.html" rel="external">
          "Bronchiectasis in adults: Treatment of acute and recurrent exacerbations"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Physician-patient partnership
         </strong>
         – Bronchiectasis is a chronic disease that requires prompt responses to exacerbations and, for many patients, daily therapy at home. Partnerships between patients and the clinical team (physicians, nurses, respiratory therapists, pharmacists) are essential to the development of successful management plans and reinforcement of treatment modalities. We establish an active partnership with patients to identify goals that are important to them and work with them to develop a management plan to achieve these goals. (See
         <a class="local">
          'Physician-patient partnership'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Nonpharmacologic therapies
         </strong>
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Airway clearance
         </strong>
         – We suggest that all patients with bronchiectasis regularly use airway clearance techniques to help remove airway secretions (
         <a class="grade" href="https:///uptodate/show/grade_6" rel="external">
          Grade 2C
         </a>
         ). Airway clearance techniques are listed in the table  (
         <a class="graphic graphic_table graphicRef78373" href="/z/d/graphic/78373.html" rel="external">
          table 1
         </a>
         ). (See
         <a class="local">
          'Airway clearance therapy'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Mucolytic therapy and airway hydration
         </strong>
         – There are insufficient data to advocate routine use of nebulized hypertonic
         <a class="drug drug_general" data-topicid="9929" href="/z/d/drug information/9929.html" rel="external">
          saline
         </a>
         , inhaled
         <a class="drug drug_general" data-topicid="9587" href="/z/d/drug information/9587.html" rel="external">
          mannitol
         </a>
         , or
         <a class="drug drug_general" data-topicid="9317" href="/z/d/drug information/9317.html" rel="external">
          acetylcysteine
         </a>
         in patients with bronchiectasis. We use hypertonic saline in patients with viscid sputum or frequent exacerbations. Use of inhaled dornase (DNase) has not been shown to be beneficial as a mucolytic agent in noncystic fibrosis bronchiectasis and may be deleterious. (See
         <a class="local">
          'Mucolytic agents and airway hydration'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Pulmonary rehabilitation
         </strong>
         – We offer pulmonary rehabilitation to patients with moderate-to-severe airflow limitation on pulmonary function testing. (See
         <a class="local">
          'Pulmonary rehabilitation'
         </a>
         above and
         <a class="medical medical_review" href="/z/d/html/1463.html" rel="external">
          "Pulmonary rehabilitation"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Evaluation of underlying diseases
         </strong>
         – We evaluate for underlying diseases (eg, nontuberculous mycobacterial infection, immunodeficiency, cystic fibrosis, recurrent aspiration, allergic bronchopulmonary aspergillosis, tracheobronchomegaly, rheumatic disease) for which specific therapy may interrupt progression of bronchiectasis. (See
         <a class="local">
          'Underlying diseases that need treatment'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Antibiotics for prevention of exacerbations
         </strong>
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Patients without chronic
         </strong>
         <strong>
          <em>
           Pseudomonas
          </em>
         </strong>
         – For patients who have recurrent exacerbations and do not have
         <em>
          Pseudomonas aeruginosa
         </em>
         infection, we suggest preventive therapy with a macrolide antibiotic (
         <a class="grade" href="https:///uptodate/show/grade_5" rel="external">
          Grade 2B
         </a>
         ). Our threshold for the initiation of preventive antibiotics is two to three exacerbations within one year. We obtain sputum stains and cultures to exclude nontuberculous mycobacterial (NTM) infection prior to initiating long-term macrolide therapy. (See
         <a class="local">
          'Macrolides'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Patients with chronic
         </strong>
         <strong>
          <em>
           Pseudomonas
          </em>
         </strong>
         <strong>
          –
         </strong>
         For patients with three or more exacerbations per year, or significant morbidity from fewer exacerbations, and
         <em>
          P. aeruginosa
         </em>
         in their sputum, we suggest a therapeutic trial of inhaled
         <a class="drug drug_general" data-topicid="10000" href="/z/d/drug information/10000.html" rel="external">
          tobramycin
         </a>
         (
         <a class="grade" href="https:///uptodate/show/grade_6" rel="external">
          Grade 2C
         </a>
         ). Treatment with inhaled tobramycin may also be reasonable for patients not infected with
         <em>
          P. aeruginosa
         </em>
         in whom oral antibiotic prophylaxis is contraindicated, not tolerated, or ineffective. (See
         <a class="local">
          'Inhaled antibiotics'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         Patients who experience bronchospasm with a test dose of inhaled antibiotic require premedication with a short-acting bronchodilator (eg, a beta-agonist). (See
         <a class="local">
          'Inhaled antibiotics'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Patients who have
         <em>
          P. aeruginosa
         </em>
         but cannot take an inhaled antibiotic may benefit from macrolide therapy as an alternative. (See
         <a class="local">
          'Patient selection (indications, contraindications, caveats)'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Avoidance of glucocorticoids
         </strong>
         – Inhaled glucocorticoids should not be routinely used in patients with bronchiectasis unless they are indicated for control of concomitant asthma or COPD. Systemic glucocorticoids should be reserved for acute exacerbations with wheezing suggestive of asthma or COPD and should accompany antibacterial therapy. (See
         <a class="local">
          'Anti-inflammatory medications'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Other medical therapies
         </strong>
         – Inhaled bronchodilators, medications to reduce gastroesophageal reflux, and immunization are appropriate in selected patients. For patients with bronchiectasis and reversible airflow limitation on spirometry, we suggest a trial of inhaled beta-adrenergic agents (
         <a class="grade" href="https:///uptodate/show/grade_6" rel="external">
          Grade 2C
         </a>
         ). (See
         <a class="local">
          'Other medical therapies'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Prognosis
         </strong>
         – The prognosis of bronchiectasis is influenced by the underlying disease process, frequency of exacerbations, and comorbidities, but overall, the age-adjusted mortality is increase compared with the general population. (See
         <a class="local">
          'Prognosis'
         </a>
         above.)
        </p>
        <p>
        </p>
       </div>
       <div class="headingAnchor" id="references">
        <ol id="reference">
         <li>
          <a class="nounderline abstract_t">
           Chalmers JD, Aliberti S, Blasi F. Management of bronchiectasis in adults. Eur Respir J 2015; 45:1446.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Polverino E, Goeminne PC, McDonnell MJ, et al. European Respiratory Society guidelines for the management of adult bronchiectasis. Eur Respir J 2017; 50.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           O'Neill K, O'Donnell AE, Bradley JM. Airway clearance, mucoactive therapies and pulmonary rehabilitation in bronchiectasis. Respirology 2019; 24:227.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Herrero-Cortina B, Lee AL, Oliveira A, et al. European Respiratory Society statement on airway clearance techniques in adults with bronchiectasis. Eur Respir J 2023; 62.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Franks LJ, Walsh JR, Hall K, Morris NR. Measuring airway clearance outcomes in bronchiectasis: a review. Eur Respir Rev 2020; 29.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hill AT, Barker AF, Bolser DC, et al. Treating Cough Due to Non-CF and CF Bronchiectasis With Nonpharmacological Airway Clearance: CHEST Expert Panel Report. Chest 2018; 153:986.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Flude LJ, Agent P, Bilton D. Chest physiotherapy techniques in bronchiectasis. Clin Chest Med 2012; 33:351.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           McIlwaine M, Bradley J, Elborn JS, Moran F. Personalising airway clearance in chronic lung disease. Eur Respir Rev 2017; 26.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Solomon GM, Barker AF, McSpiritt E, et al. Pilot Evaluation of a Management Toolkit for Airway Clearance Therapy in Bronchiectasis (IMPACT BE). ATS Sch 2023; 4:76.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lee AL, Burge AT, Holland AE. Positive expiratory pressure therapy versus other airway clearance techniques for bronchiectasis. Cochrane Database Syst Rev 2017; 9:CD011699.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kellett F, Robert NM. Nebulised 7% hypertonic saline improves lung function and quality of life in bronchiectasis. Respir Med 2011; 105:1831.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hart A, Sugumar K, Milan SJ, et al. Inhaled hyperosmolar agents for bronchiectasis. Cochrane Database Syst Rev 2014; :CD002996.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wills PJ, Hall RL, Chan W, Cole PJ. Sodium chloride increases the ciliary transportability of cystic fibrosis and bronchiectasis sputum on the mucus-depleted bovine trachea. J Clin Invest 1997; 99:9.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Nicolson CH, Stirling RG, Borg BM, et al. The long term effect of inhaled hypertonic saline 6% in non-cystic fibrosis bronchiectasis. Respir Med 2012; 106:661.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bilton D, Tino G, Barker AF, et al. Inhaled mannitol for non-cystic fibrosis bronchiectasis: a randomised, controlled trial. Thorax 2014; 69:1073.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gao YH, Abo Leyah H, Finch S, et al. Relationship between Symptoms, Exacerbations, and Treatment Response in Bronchiectasis. Am J Respir Crit Care Med 2020; 201:1499.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wilkinson M, Sugumar K, Milan SJ, et al. Mucolytics for bronchiectasis. Cochrane Database Syst Rev 2014; :CD001289.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tam J, Nash EF, Ratjen F, et al. Nebulized and oral thiol derivatives for pulmonary disease in cystic fibrosis. Cochrane Database Syst Rev 2013; :CD007168.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Fuchs HJ, Borowitz DS, Christiansen DH, et al. Effect of aerosolized recombinant human DNase on exacerbations of respiratory symptoms and on pulmonary function in patients with cystic fibrosis. The Pulmozyme Study Group. N Engl J Med 1994; 331:637.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           O'Donnell AE, Barker AF, Ilowite JS, Fick RB. Treatment of idiopathic bronchiectasis with aerosolized recombinant human DNase I. rhDNase Study Group. Chest 1998; 113:1329.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lee AL, Hill CJ, McDonald CF, Holland AE. Pulmonary Rehabilitation in Individuals With Non-Cystic Fibrosis Bronchiectasis: A Systematic Review. Arch Phys Med Rehabil 2017; 98:774.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Patel S, Cole AD, Nolan CM, et al. Pulmonary rehabilitation in bronchiectasis: a propensity-matched study. Eur Respir J 2019; 53.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lee AL, Gordon CS, Osadnik CR. Exercise training for bronchiectasis. Cochrane Database Syst Rev 2021; 4:CD013110.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Diaz AA, Colangelo LA, Okajima Y, et al. Association between Cardiorespiratory Fitness and Bronchiectasis at CT: A Long-term Population-based Study of Healthy Young Adults Aged 18-30 Years in the CARDIA Study. Radiology 2021; 300:190.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Olveira G, Olveira C, Doña E, et al. Oral supplement enriched in HMB combined with pulmonary rehabilitation improves body composition and health related quality of life in patients with bronchiectasis (Prospective, Randomised Study). Clin Nutr 2016; 35:1015.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Chalmers JD, Ringshausen FC, Harris B, et al. Cross-infection risk in patients with bronchiectasis: a position statement from the European Bronchiectasis Network (EMBARC), EMBARC/ELF patient advisory group and European Reference Network (ERN-Lung) Bronchiectasis Network. Eur Respir J 2018; 51.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Henkle E, Chan B, Curtis JR, et al. Characteristics and Health-care Utilization History of Patients With Bronchiectasis in US Medicare Enrollees With Prescription Drug Plans, 2006 to 2014. Chest 2018; 154:1311.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Goeminne PC, Scheers H, Decraene A, et al. Risk factors for morbidity and death in non-cystic fibrosis bronchiectasis: a retrospective cross-sectional analysis of CT diagnosed bronchiectatic patients. Respir Res 2012; 13:21.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Aksamit TR, O'Donnell AE, Barker A, et al. Adult Patients With Bronchiectasis: A First Look at the US Bronchiectasis Research Registry. Chest 2017; 151:982.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Md Yusof MY, Iqbal K, Darby M, et al. Effect of rituximab or tumour necrosis factor inhibitors on lung infection and survival in rheumatoid arthritis-associated bronchiectasis. Rheumatology (Oxford) 2020; 59:2838.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wang Y, Yang HB. Effects of functional endoscopic sinus surgery on the treatment of bronchiectasis combined with chronic rhino-sinusitis. Acta Otolaryngol 2016; 136:860.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Odell DD, Shah A, Gangadharan SP, et al. Airway stenting and tracheobronchoplasty improve respiratory symptoms in Mounier-Kuhn syndrome. Chest 2011; 140:867.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Quint JK, Millett ER, Joshi M, et al. Changes in the incidence, prevalence and mortality of bronchiectasis in the UK from 2004 to 2013: a population-based cohort study. Eur Respir J 2016; 47:186.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           McDonnell MJ, Aliberti S, Goeminne PC, et al. Comorbidities and the risk of mortality in patients with bronchiectasis: an international multicentre cohort study. Lancet Respir Med 2016; 4:969.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Chalmers JD, Aliberti S, Filonenko A, et al. Characterization of the "Frequent Exacerbator Phenotype" in Bronchiectasis. Am J Respir Crit Care Med 2018; 197:1410.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Watt AP, Brown V, Courtney J, et al. Neutrophil apoptosis, proinflammatory mediators and cell counts in bronchiectasis. Thorax 2004; 59:231.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Spencer S, Felix LM, Milan SJ, et al. Oral versus inhaled antibiotics for bronchiectasis. Cochrane Database Syst Rev 2018; 3:CD012579.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sadikot RT, Blackwell TS, Christman JW, Prince AS. Pathogen-host interactions in Pseudomonas aeruginosa pneumonia. Am J Respir Crit Care Med 2005; 171:1209.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wilson CB, Jones PW, O'Leary CJ, et al. Effect of sputum bacteriology on the quality of life of patients with bronchiectasis. Eur Respir J 1997; 10:1754.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Martínez-García MA, Soler-Cataluña JJ, Perpiñá-Tordera M, et al. Factors associated with lung function decline in adult patients with stable non-cystic fibrosis bronchiectasis. Chest 2007; 132:1565.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kelly C, Chalmers JD, Crossingham I, et al. Macrolide antibiotics for bronchiectasis. Cochrane Database Syst Rev 2018; 3:CD012406.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wong C, Jayaram L, Karalus N, et al. Azithromycin for prevention of exacerbations in non-cystic fibrosis bronchiectasis (EMBRACE): a randomised, double-blind, placebo-controlled trial. Lancet 2012; 380:660.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Altenburg J, de Graaff CS, Stienstra Y, et al. Effect of azithromycin maintenance treatment on infectious exacerbations among patients with non-cystic fibrosis bronchiectasis: the BAT randomized controlled trial. JAMA 2013; 309:1251.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wu Q, Shen W, Cheng H, Zhou X. Long-term macrolides for non-cystic fibrosis bronchiectasis: a systematic review and meta-analysis. Respirology 2014; 19:321.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Shi ZL, Peng H, Hu XW, Hu JG. Effectiveness and safety of macrolides in bronchiectasis patients: a meta-analysis and systematic review. Pulm Pharmacol Ther 2014; 28:171.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Chalmers JD, Boersma W, Lonergan M, et al. Long-term macrolide antibiotics for the treatment of bronchiectasis in adults: an individual participant data meta-analysis. Lancet Respir Med 2019; 7:845.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Serisier DJ, Martin ML, McGuckin MA, et al. Effect of long-term, low-dose erythromycin on pulmonary exacerbations among patients with non-cystic fibrosis bronchiectasis: the BLESS randomized controlled trial. JAMA 2013; 309:1260.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rogers GB, Bruce KD, Martin ML, et al. The effect of long-term macrolide treatment on respiratory microbiota composition in non-cystic fibrosis bronchiectasis: an analysis from the randomised, double-blind, placebo-controlled BLESS trial. Lancet Respir Med 2014; 2:988.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Anwar GA, Bourke SC, Afolabi G, et al. Effects of long-term low-dose azithromycin in patients with non-CF bronchiectasis. Respir Med 2008; 102:1494.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pasteur MC, Bilton D, Hill AT, British Thoracic Society Bronchiectasis non-CF Guideline Group. British Thoracic Society guideline for non-CF bronchiectasis. Thorax 2010; 65 Suppl 1:i1.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Chang AB, Bell SC, Torzillo PJ, et al. Chronic suppurative lung disease and bronchiectasis in children and adults in Australia and New Zealand Thoracic Society of Australia and New Zealand guidelines. Med J Aust 2015; 202:21.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Laska IF, Crichton ML, Shoemark A, Chalmers JD. The efficacy and safety of inhaled antibiotics for the treatment of bronchiectasis in adults: a systematic review and meta-analysis. Lancet Respir Med 2019; 7:855.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Elborn JS, Blasi F, Haworth CS, et al. Bronchiectasis and inhaled tobramycin: A literature review. Respir Med 2022; 192:106728.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Loebinger MR, Polverino E, Chalmers JD, et al. Efficacy and safety of TOBI Podhaler in Pseudomonas aeruginosa-infected bronchiectasis patients: iBEST study. Eur Respir J 2021; 57.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Barker AF, Couch L, Fiel SB, et al. Tobramycin solution for inhalation reduces sputum Pseudomonas aeruginosa density in bronchiectasis. Am J Respir Crit Care Med 2000; 162:481.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Scheinberg P, Shore E. A pilot study of the safety and efficacy of tobramycin solution for inhalation in patients with severe bronchiectasis. Chest 2005; 127:1420.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Drobnic ME, Suñé P, Montoro JB, et al. Inhaled tobramycin in non-cystic fibrosis patients with bronchiectasis and chronic bronchial infection with Pseudomonas aeruginosa. Ann Pharmacother 2005; 39:39.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Orriols R, Hernando R, Ferrer A, et al. Eradication Therapy against Pseudomonas aeruginosa in Non-Cystic Fibrosis Bronchiectasis. Respiration 2015; 90:299.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Guan WJ, Xu JF, Luo H, et al. A Double-Blind Randomized Placebo-Controlled Phase 3 Trial of Tobramycin Inhalation Solution in Adults With Bronchiectasis With Pseudomonas aeruginosa Infection. Chest 2023; 163:64.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Barker AF, O'Donnell AE, Flume P, et al. Aztreonam for inhalation solution in patients with non-cystic fibrosis bronchiectasis (AIR-BX1 and AIR-BX2): two randomised double-blind, placebo-controlled phase 3 trials. Lancet Respir Med 2014; 2:738.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sibila O, Laserna E, Shoemark A, et al. Airway Bacterial Load and Inhaled Antibiotic Response in Bronchiectasis. Am J Respir Crit Care Med 2019; 200:33.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Crichton ML, Lonergan M, Barker AF, et al. Inhaled aztreonam improves symptoms of cough and sputum production in patients with bronchiectasis: a post hoc analysis of the AIR-BX studies. Eur Respir J 2020; 56.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Haworth CS, Foweraker JE, Wilkinson P, et al. Inhaled colistin in patients with bronchiectasis and chronic Pseudomonas aeruginosa infection. Am J Respir Crit Care Med 2014; 189:975.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Haworth CS, Shteinberg M, Winthrop KL, et al. RCT Abstract - The efficacy and safety of colistimethate sodium delivered via the I-neb in bronchiectasis: the PROMIS-I randomized controlled trial. Eur Respir J Suppl 2021; 58.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Murray MP, Govan JR, Doherty CJ, et al. A randomized controlled trial of nebulized gentamicin in non-cystic fibrosis bronchiectasis. Am J Respir Crit Care Med 2011; 183:491.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           White L, Mirrani G, Grover M, et al. Outcomes of Pseudomonas eradication therapy in patients with non-cystic fibrosis bronchiectasis. Respir Med 2012; 106:356.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Martínez-García MÁ, Soler-Cataluña JJ, Catalán-Serra P, et al. Clinical efficacy and safety of budesonide-formoterol in non-cystic fibrosis bronchiectasis. Chest 2012; 141:461.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Goyal V, Chang AB. Combination inhaled corticosteroids and long-acting beta2-agonists for children and adults with bronchiectasis. Cochrane Database Syst Rev 2014; :CD010327.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           van der Veer T, de Koning Gans JM, Braunstahl GJ, et al. The effect of beclomethasone-formoterol versus placebo on chronic cough in patients with non-CF bronchiectasis: the FORZA randomised controlled trial. Eur Respir J 2023; 61.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Jayaram L, Vandal AC, Chang CL, et al. Tiotropium treatment for bronchiectasis: a randomised, placebo-controlled, crossover trial. Eur Respir J 2022; 59.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kapur N, Petsky HL, Bell S, et al. Inhaled corticosteroids for bronchiectasis. Cochrane Database Syst Rev 2018; 5:CD000996.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Aliberti S, Sotgiu G, Blasi F, et al. Blood eosinophils predict inhaled fluticasone response in bronchiectasis. Eur Respir J 2020; 56.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Martínez-García MÁ, Méndez R, Olveira C, et al. The U-Shaped Relationship Between Eosinophil Count and Bronchiectasis Severity: The Effect of Inhaled Corticosteroids. Chest 2023; 164:606.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Henkle E, Aksamit TR, Barker AF, et al. Pharmacotherapy for Non-Cystic Fibrosis Bronchiectasis: Results From an NTM Info &amp; Research Patient Survey and the Bronchiectasis and NTM Research Registry. Chest 2017; 152:1120.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Holme J, Tomlinson JW, Stockley RA, et al. Adrenal suppression in bronchiectasis and the impact of inhaled corticosteroids. Eur Respir J 2008; 32:1047.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lee AS, Lee JS, He Z, Ryu JH. Reflux-Aspiration in Chronic Lung Disease. Ann Am Thorac Soc 2020; 17:155.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           McDonnell MJ, O'Toole D, Ward C, et al. A qualitative synthesis of gastro-oesophageal reflux in bronchiectasis: Current understanding and future risk. Respir Med 2018; 141:132.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Fortunato GA, Machado MM, Andrade CF, et al. Prevalence of gastroesophageal reflux in lung transplant candidates with advanced lung disease. J Bras Pneumol 2008; 34:772.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           McDonnell MJ, Ahmed M, Das J, et al. Hiatal hernias are correlated with increased severity of non-cystic fibrosis bronchiectasis. Respirology 2015; 20:749.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Chang CC, Singleton RJ, Morris PS, Chang AB. Pneumococcal vaccines for children and adults with bronchiectasis. Cochrane Database Syst Rev 2009; :CD006316.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Furumoto A, Ohkusa Y, Chen M, et al. Additive effect of pneumococcal vaccine and influenza vaccine on acute exacerbation in patients with chronic lung disease. Vaccine 2008; 26:4284.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           De Soyza A, Aksamit T, Bandel TJ, et al. RESPIRE 1: a phase III placebo-controlled randomised trial of ciprofloxacin dry powder for inhalation in non-cystic fibrosis bronchiectasis. Eur Respir J 2018; 51.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Haworth CS, Bilton D, Chalmers JD, et al. Inhaled liposomal ciprofloxacin in patients with non-cystic fibrosis bronchiectasis and chronic lung infection with Pseudomonas aeruginosa (ORBIT-3 and ORBIT-4): two phase 3, randomised controlled trials. Lancet Respir Med 2019; 7:213.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kapur N, Chang AB. Oral non steroid anti-inflammatories for children and adults with bronchiectasis. Cochrane Database Syst Rev 2007; :CD006427.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pizzutto SJ, Upham JW, Yerkovich ST, Chang AB. Inhaled non-steroid anti-inflammatories for children and adults with bronchiectasis. Cochrane Database Syst Rev 2016; :CD007525.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mandal P, Chalmers JD, Graham C, et al. Atorvastatin as a stable treatment in bronchiectasis: a randomised controlled trial. Lancet Respir Med 2014; 2:455.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bedi P, Chalmers JD, Graham C, et al. A Randomized Controlled Trial of Atorvastatin in Patients With Bronchiectasis Infected With Pseudomonas Aeruginosa: A Proof of Concept Study. Chest 2017; 152:368.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hester KLM, Newton J, Rapley T, et al. Information and education provision in bronchiectasis: co-development and evaluation of a novel patient-driven resource in a digital era. Eur Respir J 2018; 51.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hill AT, Sullivan AL, Chalmers JD, et al. British Thoracic Society Guideline for bronchiectasis in adults. Thorax 2019; 74:1.
          </a>
         </li>
         <li class="breakAll">
          British Thoracic Society. Bronchiectasis Self-Management Plan. https://www.brit-thoracic.org.uk/quality-improvement/quality-standards/bronchiectasis/ (Accessed on September 07, 2020).
         </li>
         <li>
          <a class="nounderline abstract_t">
           Dupont M, Gacouin A, Lena H, et al. Survival of patients with bronchiectasis after the first ICU stay for respiratory failure. Chest 2004; 125:1815.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Alzeer AH, Al-Mobeirek AF, Al-Otair HA, et al. Right and left ventricular function and pulmonary artery pressure in patients with bronchiectasis. Chest 2008; 133:468.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Loebinger MR, Wells AU, Hansell DM, et al. Mortality in bronchiectasis: a long-term study assessing the factors influencing survival. Eur Respir J 2009; 34:843.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Smith MP, Hill AT. Evaluating success of therapy for bronchiectasis: what end points to use? Clin Chest Med 2012; 33:329.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Chalmers JD, Goeminne P, Aliberti S, et al. The bronchiectasis severity index. An international derivation and validation study. Am J Respir Crit Care Med 2014; 189:576.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Amati F, Simonetta E, Gramegna A, et al. The biology of pulmonary exacerbations in bronchiectasis. Eur Respir Rev 2019; 28.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Martínez-García MÁ, de Gracia J, Vendrell Relat M, et al. Multidimensional approach to non-cystic fibrosis bronchiectasis: the FACED score. Eur Respir J 2014; 43:1357.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ellis HC, Cowman S, Fernandes M, et al. Predicting mortality in bronchiectasis using bronchiectasis severity index and FACED scores: a 19-year cohort study. Eur Respir J 2016; 47:482.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           McDonnell MJ, Aliberti S, Goeminne PC, et al. Multidimensional severity assessment in bronchiectasis: an analysis of seven European cohorts. Thorax 2016; 71:1110.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Aliberti S, Lonni S, Dore S, et al. Clinical phenotypes in adult patients with bronchiectasis. Eur Respir J 2016; 47:1113.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Phua J, Ang YL, See KC, et al. Noninvasive and invasive ventilation in acute respiratory failure associated with bronchiectasis. Intensive Care Med 2010; 36:638.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Navaratnam V, Muirhead CR, Hubbard RB, De Soyza A. Critical care admission trends and outcomes in individuals with bronchiectasis in the UK. QJM 2016; 109:523.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Goeminne PC, Nawrot TS, Ruttens D, et al. Mortality in non-cystic fibrosis bronchiectasis: a prospective cohort analysis. Respir Med 2014; 108:287.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Clayton TC, Thompson M, Meade TW. Recent respiratory infection and risk of cardiovascular disease: case-control study through a general practice database. Eur Heart J 2008; 29:96.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Navaratnam V, Root AA, Douglas I, et al. Cardiovascular Outcomes after a Respiratory Tract Infection among Adults with Non-Cystic Fibrosis Bronchiectasis: A General Population-based Study. Ann Am Thorac Soc 2018; 15:315.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Navaratnam V, Millett ER, Hurst JR, et al. Bronchiectasis and the risk of cardiovascular disease: a population-based study. Thorax 2017; 72:161.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Huang JT, Kuzmanova E, Dicker AJ, et al. Serum Desmosine Is Associated with Long-Term All-Cause and Cardiovascular Mortality in Bronchiectasis. Am J Respir Crit Care Med 2020; 202:897.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Choi H, Park HY, Han K, et al. Non-Cystic Fibrosis Bronchiectasis Increases the Risk of Lung Cancer Independent of Smoking Status. Ann Am Thorac Soc 2022; 19:1551.
          </a>
         </li>
        </ol>
       </div>
       <div id="topicVersionRevision">
        Topic 129310 Version 20.0
       </div>
      </div>
      <div class="row">
       <div class="col-12">
        <h4 style="text-align: center;padding: 20px;color: cadetblue;">
         References
        </h4>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25792635" id="rid0" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          1 : Management of bronchiectasis in adults.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28889110" id="rid1" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          2 : European Respiratory Society guidelines for the management of adult bronchiectasis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30650472" id="rid2" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          3 : Airway clearance, mucoactive therapies and pulmonary rehabilitation in bronchiectasis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/37142337" id="rid3" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          4 : European Respiratory Society statement on airway clearance techniques in adults with bronchiectasis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32350088" id="rid4" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          5 : Measuring airway clearance outcomes in bronchiectasis: a review.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29355548" id="rid5" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          6 : Treating Cough Due to Non-CF and CF Bronchiectasis With Nonpharmacological Airway Clearance: CHEST Expert Panel Report.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22640850" id="rid6" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          7 : Chest physiotherapy techniques in bronchiectasis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28223396" id="rid7" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          8 : Personalising airway clearance in chronic lung disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/37089683" id="rid8" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          9 : Pilot Evaluation of a Management Toolkit for Airway Clearance Therapy in Bronchiectasis (IMPACT BE).
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28952156" id="rid9" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          10 : Positive expiratory pressure therapy versus other airway clearance techniques for bronchiectasis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22018993" id="rid10" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          11 : Nebulised 7% hypertonic saline improves lung function and quality of life in bronchiectasis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24817558" id="rid11" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          12 : Inhaled hyperosmolar agents for bronchiectasis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9011581" id="rid12" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          13 : Sodium chloride increases the ciliary transportability of cystic fibrosis and bronchiectasis sputum on the mucus-depleted bovine trachea.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22349069" id="rid13" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          14 : The long term effect of inhaled hypertonic saline 6% in non-cystic fibrosis bronchiectasis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25246664" id="rid14" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          15 : Inhaled mannitol for non-cystic fibrosis bronchiectasis: a randomised, controlled trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32097051" id="rid15" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          16 : Relationship between Symptoms, Exacerbations, and Treatment Response in Bronchiectasis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24789119" id="rid16" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          17 : Mucolytics for bronchiectasis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23852992" id="rid17" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          18 : Nebulized and oral thiol derivatives for pulmonary disease in cystic fibrosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7503821" id="rid18" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          19 : Effect of aerosolized recombinant human DNase on exacerbations of respiratory symptoms and on pulmonary function in patients with cystic fibrosis. The Pulmozyme Study Group.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9596315" id="rid19" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          20 : Treatment of idiopathic bronchiectasis with aerosolized recombinant human DNase I. rhDNase Study Group.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27320420" id="rid20" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          21 : Pulmonary Rehabilitation in Individuals With Non-Cystic Fibrosis Bronchiectasis: A Systematic Review.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30578381" id="rid21" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          22 : Pulmonary rehabilitation in bronchiectasis: a propensity-matched study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33822364" id="rid22" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          23 : Exercise training for bronchiectasis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33904771" id="rid23" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          24 : Association between Cardiorespiratory Fitness and Bronchiectasis at CT: A Long-term Population-based Study of Healthy Young Adults Aged 18-30 Years in the CARDIA Study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26522923" id="rid24" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          25 : Oral supplement enriched in HMB combined with pulmonary rehabilitation improves body composition and health related quality of life in patients with bronchiectasis (Prospective, Randomised Study).
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29326319" id="rid25" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          26 : Cross-infection risk in patients with bronchiectasis: a position statement from the European Bronchiectasis Network (EMBARC), EMBARC/ELF patient advisory group and European Reference Network (ERN-Lung) Bronchiectasis Network.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30055168" id="rid26" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          27 : Characteristics and Health-care Utilization History of Patients With Bronchiectasis in US Medicare Enrollees With Prescription Drug Plans, 2006 to 2014.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22423975" id="rid27" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          28 : Risk factors for morbidity and death in non-cystic fibrosis bronchiectasis: a retrospective cross-sectional analysis of CT diagnosed bronchiectatic patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27889361" id="rid28" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          29 : Adult Patients With Bronchiectasis: A First Look at the US Bronchiectasis Research Registry.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32065634" id="rid29" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          30 : Effect of rituximab or tumour necrosis factor inhibitors on lung infection and survival in rheumatoid arthritis-associated bronchiectasis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27002736" id="rid30" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          31 : Effects of functional endoscopic sinus surgery on the treatment of bronchiectasis combined with chronic rhino-sinusitis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21493699" id="rid31" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          32 : Airway stenting and tracheobronchoplasty improve respiratory symptoms in Mounier-Kuhn syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26541539" id="rid32" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          33 : Changes in the incidence, prevalence and mortality of bronchiectasis in the UK from 2004 to 2013: a population-based cohort study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27864036" id="rid33" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          34 : Comorbidities and the risk of mortality in patients with bronchiectasis: an international multicentre cohort study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29357265" id="rid34" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          35 : Characterization of the "Frequent Exacerbator Phenotype" in Bronchiectasis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/14985560" id="rid35" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          36 : Neutrophil apoptosis, proinflammatory mediators and cell counts in bronchiectasis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29587336" id="rid36" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          37 : Oral versus inhaled antibiotics for bronchiectasis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15695491" id="rid37" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          38 : Pathogen-host interactions in Pseudomonas aeruginosa pneumonia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9272915" id="rid38" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          39 : Effect of sputum bacteriology on the quality of life of patients with bronchiectasis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17998359" id="rid39" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          40 : Factors associated with lung function decline in adult patients with stable non-cystic fibrosis bronchiectasis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29543980" id="rid40" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          41 : Macrolide antibiotics for bronchiectasis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22901887" id="rid41" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          42 : Azithromycin for prevention of exacerbations in non-cystic fibrosis bronchiectasis (EMBRACE): a randomised, double-blind, placebo-controlled trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23532241" id="rid42" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          43 : Effect of azithromycin maintenance treatment on infectious exacerbations among patients with non-cystic fibrosis bronchiectasis: the BAT randomized controlled trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24417869" id="rid43" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          44 : Long-term macrolides for non-cystic fibrosis bronchiectasis: a systematic review and meta-analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24076368" id="rid44" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          45 : Effectiveness and safety of macrolides in bronchiectasis patients: a meta-analysis and systematic review.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31405828" id="rid45" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          46 : Long-term macrolide antibiotics for the treatment of bronchiectasis in adults: an individual participant data meta-analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23532242" id="rid46" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          47 : Effect of long-term, low-dose erythromycin on pulmonary exacerbations among patients with non-cystic fibrosis bronchiectasis: the BLESS randomized controlled trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25458200" id="rid47" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          48 : The effect of long-term macrolide treatment on respiratory microbiota composition in non-cystic fibrosis bronchiectasis: an analysis from the randomised, double-blind, placebo-controlled BLESS trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18653323" id="rid48" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          49 : Effects of long-term low-dose azithromycin in patients with non-CF bronchiectasis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20627931" id="rid49" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          50 : British Thoracic Society guideline for non-CF bronchiectasis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25588439" id="rid50" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          51 : Chronic suppurative lung disease and bronchiectasis in children and adults in Australia and New Zealand Thoracic Society of Australia and New Zealand guidelines.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31405826" id="rid51" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          52 : The efficacy and safety of inhaled antibiotics for the treatment of bronchiectasis in adults: a systematic review and meta-analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34998112" id="rid52" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          53 : Bronchiectasis and inhaled tobramycin: A literature review.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32855225" id="rid53" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          54 : Efficacy and safety of TOBI Podhaler in Pseudomonas aeruginosa-infected bronchiectasis patients: iBEST study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10934074" id="rid54" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          55 : Tobramycin solution for inhalation reduces sputum Pseudomonas aeruginosa density in bronchiectasis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15821224" id="rid55" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          56 : A pilot study of the safety and efficacy of tobramycin solution for inhalation in patients with severe bronchiectasis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15562142" id="rid56" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          57 : Inhaled tobramycin in non-cystic fibrosis patients with bronchiectasis and chronic bronchial infection with Pseudomonas aeruginosa.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26340658" id="rid57" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          58 : Eradication Therapy against Pseudomonas aeruginosa in Non-Cystic Fibrosis Bronchiectasis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/35863486" id="rid58" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          59 : A Double-Blind Randomized Placebo-Controlled Phase 3 Trial of Tobramycin Inhalation Solution in Adults With Bronchiectasis With Pseudomonas aeruginosa Infection.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25154045" id="rid59" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          60 : Aztreonam for inhalation solution in patients with non-cystic fibrosis bronchiectasis (AIR-BX1 and AIR-BX2): two randomised double-blind, placebo-controlled phase 3 trials.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31109172" id="rid60" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          61 : Airway Bacterial Load and Inhaled Antibiotic Response in Bronchiectasis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32265309" id="rid61" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          62 : Inhaled aztreonam improves symptoms of cough and sputum production in patients with bronchiectasis: a post hoc analysis of the AIR-BX studies.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24625200" id="rid62" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          63 : Inhaled colistin in patients with bronchiectasis and chronic Pseudomonas aeruginosa infection.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid63" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          64 : RCT Abstract - The efficacy and safety of colistimethate sodium delivered via the I-neb in bronchiectasis: the PROMIS-I randomized controlled trial
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20870753" id="rid64" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          65 : A randomized controlled trial of nebulized gentamicin in non-cystic fibrosis bronchiectasis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22204744" id="rid65" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          66 : Outcomes of Pseudomonas eradication therapy in patients with non-cystic fibrosis bronchiectasis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21778259" id="rid66" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          67 : Clinical efficacy and safety of budesonide-formoterol in non-cystic fibrosis bronchiectasis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24913725" id="rid67" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          68 : Combination inhaled corticosteroids and long-acting beta2-agonists for children and adults with bronchiectasis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/37263749" id="rid68" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          69 : The effect of beclomethasone-formoterol versus placebo on chronic cough in patients with non-CF bronchiectasis: the FORZA randomised controlled trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34795034" id="rid69" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          70 : Tiotropium treatment for bronchiectasis: a randomised, placebo-controlled, crossover trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29766487" id="rid70" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          71 : Inhaled corticosteroids for bronchiectasis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32398295" id="rid71" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          72 : Blood eosinophils predict inhaled fluticasone response in bronchiectasis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/37088355" id="rid72" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          73 : The U-Shaped Relationship Between Eosinophil Count and Bronchiectasis Severity: The Effect of Inhaled Corticosteroids.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28479113" id="rid73" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          74 : Pharmacotherapy for Non-Cystic Fibrosis Bronchiectasis: Results From an NTM Info&amp;Research Patient Survey and the Bronchiectasis and NTM Research Registry.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18508829" id="rid74" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          75 : Adrenal suppression in bronchiectasis and the impact of inhaled corticosteroids.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31697575" id="rid75" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          76 : Reflux-Aspiration in Chronic Lung Disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30053958" id="rid76" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          77 : A qualitative synthesis of gastro-oesophageal reflux in bronchiectasis: Current understanding and future risk.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19009209" id="rid77" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          78 : Prevalence of gastroesophageal reflux in lung transplant candidates with advanced lung disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25872951" id="rid78" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          79 : Hiatal hernias are correlated with increased severity of non-cystic fibrosis bronchiectasis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19370631" id="rid79" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          80 : Pneumococcal vaccines for children and adults with bronchiectasis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18585831" id="rid80" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          81 : Additive effect of pneumococcal vaccine and influenza vaccine on acute exacerbation in patients with chronic lung disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29371383" id="rid81" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          82 : RESPIRE 1: a phase III placebo-controlled randomised trial of ciprofloxacin dry powder for inhalation in non-cystic fibrosis bronchiectasis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30658914" id="rid82" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          83 : Inhaled liposomal ciprofloxacin in patients with non-cystic fibrosis bronchiectasis and chronic lung infection with Pseudomonas aeruginosa (ORBIT-3 and ORBIT-4): two phase 3, randomised controlled trials.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17943909" id="rid83" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          84 : Oral non steroid anti-inflammatories for children and adults with bronchiectasis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26816298" id="rid84" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          85 : Inhaled non-steroid anti-inflammatories for children and adults with bronchiectasis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24717640" id="rid85" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          86 : Atorvastatin as a stable treatment in bronchiectasis: a randomised controlled trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28554732" id="rid86" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          87 : A Randomized Controlled Trial of Atorvastatin in Patients With Bronchiectasis Infected With Pseudomonas Aeruginosa: A Proof of Concept Study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29496753" id="rid87" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          88 : Information and education provision in bronchiectasis: co-development and evaluation of a novel patient-driven resource in a digital era.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30545985" id="rid88" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          89 : British Thoracic Society Guideline for bronchiectasis in adults.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30545985" id="rid89" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          90 : British Thoracic Society Guideline for bronchiectasis in adults.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15136395" id="rid90" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          91 : Survival of patients with bronchiectasis after the first ICU stay for respiratory failure.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18071019" id="rid91" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          92 : Right and left ventricular function and pulmonary artery pressure in patients with bronchiectasis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19357155" id="rid92" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          93 : Mortality in bronchiectasis: a long-term study assessing the factors influencing survival.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22640849" id="rid93" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          94 : Evaluating success of therapy for bronchiectasis: what end points to use?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24328736" id="rid94" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          95 : The bronchiectasis severity index. An international derivation and validation study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31748420" id="rid95" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          96 : The biology of pulmonary exacerbations in bronchiectasis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24232697" id="rid96" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          97 : Multidimensional approach to non-cystic fibrosis bronchiectasis: the FACED score.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26585428" id="rid97" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          98 : Predicting mortality in bronchiectasis using bronchiectasis severity index and FACED scores: a 19-year cohort study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27516225" id="rid98" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          99 : Multidimensional severity assessment in bronchiectasis: an analysis of seven European cohorts.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26846833" id="rid99" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          100 : Clinical phenotypes in adult patients with bronchiectasis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20052456" id="rid100" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          101 : Noninvasive and invasive ventilation in acute respiratory failure associated with bronchiectasis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26582824" id="rid101" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          102 : Critical care admission trends and outcomes in individuals with bronchiectasis in the UK.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24445062" id="rid102" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          103 : Mortality in non-cystic fibrosis bronchiectasis: a prospective cohort analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18063596" id="rid103" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          104 : Recent respiratory infection and risk of cardiovascular disease: case-control study through a general practice database.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29266966" id="rid104" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          105 : Cardiovascular Outcomes after a Respiratory Tract Infection among Adults with Non-Cystic Fibrosis Bronchiectasis: A General Population-based Study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27573451" id="rid105" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          106 : Bronchiectasis and the risk of cardiovascular disease: a population-based study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32402210" id="rid106" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          107 : Serum Desmosine Is Associated with Long-Term All-Cause and Cardiovascular Mortality in Bronchiectasis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/35533306" id="rid107" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          108 : Non-Cystic Fibrosis Bronchiectasis Increases the Risk of Lung Cancer Independent of Smoking Status.
         </p>
        </a>
       </div>
      </div>
     </div>
    </div>
   </section>
  </section>
  <!-- End Main Menu Area -->
  <!-- Start Search Popup Area -->
  <!-- End Footer Area -->
  <!-- Back to top -->
  <a class="scrolltop" href="#top">
   <i class="icofont-hand-drawn-up">
   </i>
  </a>
  <!-- End Back to top -->
  <!-- jQuery Min JS -->
  <!-- Prpper JS -->
  <!-- Bootstrap Min JS -->
  <!-- Classy Nav Min Js -->
  <!-- Owl Carousel Min Js -->
  <!-- Magnific Popup JS -->
  <!-- CounterUp JS -->
  <!-- Waypoints JS -->
  <!-- Form Validator Min JS -->
  <!-- Contact Form Min JS -->
  <!-- Main JS -->
  <!-- Global site tag (gtag.js) - Google Analytics -->
 </body>
</html>
